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Abstract 
 
Regulatory T cells represent a specialized subpopulation of T lymphocytes that 
may modulate spontaneous HIV-1 disease progression by suppressing immune 
activation or inhibiting antiviral T cell immune responses. While effects of classical 
CD25hiFoxP3+CD4+ regulatory T cells during HIV-1 infection have been analyzed in a 
series of recent investigations, very little is known about the role of non-classical 
regulatory T cells that do not express intracellular FoxP3. Here I evaluated two groups 
of non-classical Treg cells. One is phenotypically identified by the surface expression 
of HLA-G, an HLA class Ib molecule. The other Treg cell population is characterized by 
the surface expression of latency-associated peptide (LAP), a membrane-bound form 
of TGF-β. Both HLA-G and LAP-expressing T cells are present in small proportions in 
peripheral blood of healthy individuals.  
I performed a systematic study on the phenotypic and functional profile of HLA-
G- and LAP- expressing regulatory T (Treg) cells in patients with different stages of 
HIV-1 infection. I found that HLA-G-expressing Treg cells were highly susceptible to 
HIV-1 infection, and were significantly reduced in individuals with progressive HIV-1 
disease courses. Moreover, the proportion of HLA-G+ CD4 and CD8 T cells was 
positively correlated with CD4 T cell count and inversely correlated with markers of 
HIV-1 associated immune activation. Mechanistically, this correlation corresponded to 
a substantially increased ability of HLA-G+ Treg cells to inhibit bystander immune 
 iv 
activation, while only minimally affecting functional properties of HIV-1-specific T cells. 
In contrast, no significant change in LAP+ Treg cell frequencies was found in 
progressive HIV-1 infection, and these frequencies were not correlated with immune 
activation. This observation was consistent with functional analysis, which indicated 
that LAP+ Treg cells did not suppress bystander activation. These investigations 
indicate an important role of HLA-G+ Treg cells for balancing bystander immune 
activation and anti-viral immune activity in HIV-1 infection, and suggest that the loss of 
these cells during advanced HIV-1 infection may contribute to immune dysregulation 
and HIV-1 disease progression. In the meantime, LAP+ Treg cells do not appear to play 
an important role in determining HIV-1 disease outcome.  
   
 
 
 
 
 v 
Table of Contents 
 
 
Abstract ......................................................................................................................iii 
Table of Contents........................................................................................................v 
List of Figures ...........................................................................................................vii 
Acknowledgements ...................................................................................................xi 
Attributions...............................................................................................................xiii 
Abbreviations ...........................................................................................................xiv 
Chapter 1   Introduction..............................................................................................1 
HIV-1/AIDS global epidemic...................................................................2 
Molecular biology of HIV-1 .....................................................................3 
HIV-1 natural history ..............................................................................5 
Acute infection ...................................................................................6 
Clinical latency...................................................................................7 
Advanced disease .............................................................................7 
HIV-1/AIDS treatment (HAART) .............................................................7 
Important prognostic markers...............................................................10 
HIV-1 elite control ................................................................................12 
Mechanisms for HIV-1 control ..............................................................14 
Virus dynamics ................................................................................14 
Host factors .....................................................................................14 
Host immune response....................................................................15 
CD8 cytotoxic T lymphocytes (CTLs)....................................................16 
CD4 helper cells...................................................................................17 
Regulatory T (Treg) cells......................................................................19 
Treg cell markers .............................................................................20 
Mechanisms for suppression............................................................22 
Treg cells and HIV-1 infection ..........................................................23 
Current investigations ..........................................................................25 
References ..........................................................................................26 
Chapter 2   Comprehensive characterization of HLA-G-expressing regulatory T 
cells in HIV-1 infection..............................................................................................45 
Introduction ..........................................................................................46 
Materials and Methods.........................................................................48 
Results.................................................................................................55 
Discussion ...........................................................................................92 
References ..........................................................................................97 
 
 vi 
Chapter 3   Comprehensive characterization of LAP-expressing regulatory T cells 
in HIV-1 infection.....................................................................................................103 
Introduction ........................................................................................104 
Materials and Methods.......................................................................106 
Results and Discussion......................................................................110 
References ........................................................................................128 
Chapter 4   Conclusions .........................................................................................129 
Appendix   List of Publications..............................................................................137 
 
 
 vii 
List of Figures 
 
Figure 1-1 Global distribution of HIV-1-infected populations Page 3 
 
 
 
Figure 1-2 Genomic organization of HIV Page 5 
 
 
 
Figure 1-3  Natural history of HIV-1 infection Page 6 
 
 
 
Figure 1-4 HIV life cycle Page 9 
Figure 1-5  Interactions between innate immunity and adaptive 
immunity during HIV-1 infection  
Page 15 
 
 
 
Figure 1-6  CD4 T helper cell categories Page 19 
 
 
 
Figure 2-1  Co-expression of HLA-G with CD25 and FoxP3 in patients 
with different HIV-1 stages and healthy individuals  
Page 57 
 
 
 
Figure 2-2 Relative proportions and absolute counts of classical 
CD25hiCD127lo CD4 Treg cells in indicated study 
populations  
Page 58 
 
 
 
Figure 2-3 Correlation between CD25hi CD127lo CD4 T cell proportion 
and immune activation  
Page 69 
 
 
 
Figure 2-4 Diminished proportions of HLA-G+ CD4 T cells in 
progressive HIV-1 infection (representative flow plots)  
Page 60 
 
 
 
Figure 2-5 Diminished proportions of HLA-G+ CD4 T cells in 
progressive HIV-1 infection (summarized data)  
Page 61 
 
 
 
Figure 2-6 Diminished proportions of HLA-G+ CD8 T cells in 
progressive HIV-1 infection (representative flow plots) 
Page 63 
 
 
 
Figure 2-7   Diminished proportions of HLA-G+ CD8 T cells in 
progressive HIV-1 infection (summarized data)  
Page 64 
 
 
 
Figure 2-8   Proportion of HLA-G-expressing CD4 or CD8 T cells in elite 
controllers and in viremic controllers 
Page 65 
 
 
 
Figure 2-9   
 
Correlations between HLA-G+ T cell proportions and total 
CD4 T cell counts  
Page 66 
 
 
 
Figure 2-10   
 
Correlations between HLA-G+ T cell proportions and 
plasma viral load in progressors 
Page 67 
 
 
 
Figure 2-11   
 
Correlations between HLA-G+ T cell proportions and T cell 
immune activation  
Page 68 
 viii 
 
 
 
Figure 2-12  Proportion of HLA-G+ CD4 and HLA-G+ CD8 Treg cells in 
lymph node and paired peripheral blood  
Page 70 
 
 
 
Figure 2-13   CD25hiCD127lo CD4 Treg cells are enriched in lymph node 
compared to that in paired peripheral blood 
Page 71 
 
 
 
Figure 2-14   
 
T cell subset distribution of HLA-G-expressing CD4 T cells 
in indicated study populations  
Page 73 
 
 
 
Figure 2-15   Surface expression of CD57 and PD-1 in HLA-G- 
expressing CD4 T cells in indicated study cohorts  
Page 74 
 
 
 
Figure 2-16   
 
T cell subset distribution of HLA-G-expressing CD8 T cells 
in indicated study populations  
Page 75 
 
 
 
Figure 2-17   Surface expression of CD57 and PD-1 in HLA-G- 
expressing CD8 T cells in indicated study cohorts  
Page 76 
 
 
 
Figure 2-18  HLA-G+ Treg cells do not inhibit proliferative activities of 
HIV-1, CMV-, or PHA stimulated helper T cells  
Page 78 
 
 
 
Figure 2-19  HLA-G+ Treg cells do not inhibit proliferative activities of 
HIV-1, CMV-, or PHA stimulated cytotoxic T cells  
Page 79 
 
 
 
Figure 2-20 HLA-G+ Treg cells do not affect cytokine secretion 
properties of HIV-1- specific T cells  
Page 80 
 
 
 
Figure 2-21 Representative flow cytometry dot plots reflect CD38 
expression on Vβ13.1+ and Vβ13.1- responder T cells 
following exposure to HLA-G-expressing Treg cells 
Page 82 
 
 
 
Figure 2-22  Cumulative data represent relative suppression of CD38 
and HLA-DR on Vβ13.1+ and Vβ13.1- responder T cells 
following exposure to HLA-G-expressing CD4 Treg cells 
Page 83 
 
 
 
Figure 2-23 Cumulative data represent relative suppression of CD38 
and HLA-DR on Vβ13.1+ and Vβ13.1- responder T cells 
following exposure to HLA-G-expressing CD8 Treg cells 
Page 84 
 
 
 
Figure 2-24 Expression of soluble and membrane-bound HLA-G in 
culture 
Page 86 
 
 
 
Figure 2-25  LILRB1 expression on Vβ13 1+ T cells remains stable while 
that on Vβ13 1- T cells decreases 
Page 87 
 
 
 
Figure 2-26  HLA-G+ Treg cells were more susceptible to VSV-G, X4 
and R5 virus infection than the HLA-G- cells (with pre-
activation) 
Page 89 
 
 
 
 ix 
 
 
 
Figure 2-27  HLA-G+ Treg cells were more susceptible to VSV-G, X4 
and R5 virus infection than the HLA-G- cells (without pre-
activation)  
Page 90 
 
 
 
Figure 2-28 Pre-activated HLA-G+ CD4 T cells express higher level of 
HIV-1 co-receptor, CXCR4 and CCR5, during in vitro 
infection  
Page 91 
 
 
 
Figure 2-29 Non-activated HLA-G+ CD4 T cells express higher level of 
HIV-1 co-receptor, CXCR4 and CCR5, during ex vivo 
infection  
Page 92 
 
 
 
 
 
Figure 2-30 Mechanisms for direct and bystander T-cell activation Page 96 
 
 
 
Figure 3-1   LAP covalently binds to latent form of TGF-β  Page 105 
 
 
 
Figure 3-2 Proportions of LAP+ CD4 T cells in indicated study 
populations (representative flow plots) 
Page 112 
 
 
 
Figure 3-3  Relative proportions and absolute counts of LAP+ CD4 T 
cells in indicated study populations (summarized data)   
Page 113 
 
 
 
Figure 3-4 Proportions of LAP+ CD8 T cells in indicated study 
populations (representative flow plots) 
Page 114 
 
 
 
Figure 3-5  Relative proportions and absolute counts of LAP+ CD8 T 
cells in indicated study populations (summarized data) 
Page 115 
 
 
 
Figure 3-6  Correlations between proportions of LAP+ CD4 and CD8 T 
cells and CD4 T cell count 
Page 116 
 
 
 
Figure 3-7  Correlations between proportions of LAP+ T cells and 
plasma viral load  
Page 117 
 
 
 
Figure 3-8 Correlations between proportions of LAP+ T cells and T cell 
immune activation 
Page 118 
 
 
 
Figure 3-9 T cell subset distribution of LAP-expressing CD4 T cells in 
indicated study populations  
Page 119 
 
 
 
Figure 3-10 T cell subset distribution of LAP-expressing CD8 T cells in 
indicated study populations  
Page 120 
 
 
 
Figure 3-11 Surface expression of CD57 and PD-1 in LAP- expressing 
CD4 T cells in indicated study cohorts  
Page 121 
 
 
 
Figure 3-12 Surface expression of CD57 and PD-1 in LAP- expressing 
CD8 T cells in indicated study cohorts  
Page 122 
 
 
 
 x 
Figure 3-13 LAP-expressing Treg cells weakly inhibit proliferative 
activities of HIV-1 stimulated cytotoxic T cells  
Page 124 
 
 
 
Figure 3-14 LAP-expressing Treg cells do not affect cytokine secretion 
properties of HIV-1- specific T cells  
Page 125 
 
 
 
Figure 3-15 Representative flow cytometry dot plots reflect CD38 
expression on Vβ13.1+ and Vβ13.1- responder T cells 
following exposure to LAP-expressing CD4 Treg cells 
Page 127 
 
 
 
Figure 3-16 Cumulative data represent relative suppression of CD38 
and HLA-DR on Vβ13.1+ and Vβ13.1- responder T cells 
following exposure to LAP-expressing CD4 Treg cells 
Page 128 
 
 xi 
Acknowledgements 
 
I am extremely fortunate to have received strong support from many aspects of 
my life, and I am truly thankful for my advisors, thesis committee, lab-mates, friends 
and family.  
I thank my advisors Drs. Bruce Walker and Xu Yu for their intellectual 
inspiration, thoughtful guidance and generous support over the years, and for teaching 
me many life lessons along the way. I have learned an immense amount from you and 
I am very grateful to have you as my advisors. While I don’t know where I am heading 
yet, I will always see you as my role models. 
Special thanks are given to my advisory committee, Drs. Amitinder Kaur, 
Andrew Tager and Eric Sundberg for their thoughtful advice, which was invaluable for 
my every progress. I would also like to thank my exam committee, Drs. Andrew Tager, 
Dan Barouch, and Raymond Welsh, for attending my defense seminar in their very 
busy schedule.  
Thanks to all the past and present members of Walker and Yu laboratories for 
their tremendous support. I would particularly like to thank Drs. Zabrina Brumme and 
Mark Brockman, for leading me into the world of HIV research, and teaching me many 
techniques that I used in my dissertation; Dr. Mathias Lichterfeld, for giving me helpful 
guidance and advice; Dr. Jinghe Huang and Pat Burke, for teaching me flow cytometry; 
Drs. Enrique Martin-Gayo, Maria Buzon, and Jin Leng, for many helpful scientific 
discussions, and valuable input on my thesis preparation; Hong Sun and Ying Chan for 
being lovely friends, and spending many after-work hours with me.  
I am grateful to a number of friends in the Harvard Life Science Program that 
kept me sane during the craziness of graduate school. Yao Chen and Xuehong Zhang 
 xii 
for helping me with my initial transition to the US and to Harvard; Cherie Ramirez, Judy 
Liu, and Teresa Peterson for helping me survive the experience of being a graduate 
student in a Charlestown lab; Chi Zhang for being the best neighbor. 
Finally, I would like to express my deepest gratefulness to my family. To my 
husband Lin Cheng, I would not have made it without you. Thank you for being there 
whenever I need you, and sharing every bit of my happiness and bitterness. To my 
parents, Mingjin Li and Songying Yan, thanks for the unconditional love and attention 
not only to my professional accomplishments, but more importantly, to my health, 
happiness and general well-being. Thank you for loving me for the way you have. 
 
 
 
 
 xiii 
Attributions 
 
 
This work has been accepted as Chun Li, Ilona Toth, Julian Schulze zur Wiesch, 
Florencia Pereyra, Jennifer Rychert, Eric S. Rosenberg, Jan van Lunzen, Mathias 
Lichterfeld, Xu G. Yu. HLA-G+ regulatory T cells reduce bystander immune activation in 
HIV-1 infection. PLOS Pathogens, in press. 
 
 
 
I performed the experiments presented in this dissertation, with the exceptions listed 
below. 
 
 
 
Lymph node staining was performed by Ilona Toth, Julian Schulze zur Wiesch and Jan 
van Lunzen. 
 
 xiv 
 Abbreviations 
 
AIDS acquired immune deficiency syndrome 
  
APC antigen presenting cell 
  
CTL cytotoxic T lymphocyte 
  
EC elite controller 
  
HAART highly active antiretroviral therapy 
  
HIV human immunodeficiency virus 
  
HLA human leukocyte antigen 
  
IFN interferon 
  
IL interleukin 
  
LILRA leukocyte immunoglobulin-like receptor, 
subfamily A 
  
LILRB leukocyte immunoglobulin-like receptor, 
subfamily B 
  
LNMC lymph node mononuclear cell 
  
LTNP long-term nonprogressor 
  
LTR long terminal repeat 
  
mDC myeloid dendritic cells 
  
MHC major histocompatibility complex 
  
PBMC peripheral blood mononuclear cell 
  
pDC plasmacytoid dendritic cell 
  
prog progressor 
  
RT reverse transcriptase 
  
SIV simian immunodeficiency virus 
  
VC viremic controller 
1 
Chapter 1 
 
 
 
 
 
Introduction
2 
HIV-1/AIDS global epidemic 
The first case of HIV/AIDS infection was reported in 1981, when four 
homosexual men who presented with pneumocystis carinii pneumonia and mucosal 
candidiasis were found to have severely reduced helper T cells (1). Two years later, 
the “human T-cell leukemia virus” was isolated in AIDS patients (2, 3), and 
subsequently named human immunodeficiency virus (HIV) (4). 
Since then, the rapid pandemic spread of HIV/AIDS has made it one of the 
most pressing threats to global public health. It has been estimated that, in 2010, 34 
million people were living with HIV (5), 10% of whom were children under 15 years of 
age. Despite extensive efforts in prevention and treatment, 2.7 million people acquired 
the disease in 2010 and 1.8 million people were killed. HIV/AIDS has its strongest 
impact in sub-Saharan Africa, where 25.8 million people are HIV positive, and new 
infections occurs at a high rate of 1.7 million per year (6). In the US, 1.2 million 
individuals are living with the disease, and incidence rate is approximately 50,000 per 
year (Figure 1-1) (7). In addition, the virus is spreading rapidly in Latin America, 
eastern Europe, central, south and south-east Asia, with an infected population of more 
than 1 million in each region (Figure 1-1) (7). Furthermore, because HIV/AIDS 
disproportionately affects young and mid-aged individuals, AIDS-related deaths lead to 
significant loss of human capital, and seriously compromise economic development. 
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Figure 1-1. Global distribution of HIV-1-infected populations. The HIV pandemic has a 
wide impact all over the world, with its most significant influence in Sub-Saharan Africa. 
Source: UNAIDS 2010. 
 
Two subtypes of HIV are currently identified – HIV subtype 1 (HIV-1) and HIV 
subtype 2 (HIV-2). Both viruses were transferred to humans from non-human primates 
in west-central Africa: HIV-1 originated in chimpanzees, and HIV-2 originated from 
sooty mangabeys (8-10). While HIV-1 serves as the primary cause of AIDS and has a 
worldwide presence, HIV-2 is less transmittable and pathogenic (9, 11), and its 
endemic is limited to West Africa and Asia.  
 
Molecular biology of HIV-1  
HIV-1 belongs to the Lentivirus genus of the Retroviridae family. A mature HIV-
1 virion contains two copies of 9.7kb, positive-sense, single-stranded RNA genome. 
The genome is packed within an inner conical-shaped core, which is further 
 
4 
surrounded by an outer envelope derived from the host cell plasma phospholipid 
bilayer. The HIV-1 genome encodes a long terminal repeat (LTR) and nine viral genes: 
three structural genes - gag, pol, and env, and six accessory genes - tat, rev, vif, nef, 
vpr, vpu (Figure 1-2) (12). The three structural genes each encode a large poly-protein 
that goes through post-translational cleavage to yield smaller functional subunits. 
Briefly, the Gag polyprotein comprises four proteins that build the physical structure of 
the virus-capsid protein p24, matrix protein p17, and nucleocapsid proteins p6 and p7 
(13). These subunits are involved in viral packaging and uncoating processes (13). The 
Pol precursor yields the catalytic proteins protease, reverse transcriptase, and 
integrase (14); and the Env product is comprised of a gp160 protein, which is further 
cleaved into a gp41 transmembrane subunit and a surface gp120 subunit. The six 
accessory genes each produce one protein required for optimizing viral replication and 
pathogenicity (15, 16).  
The HIV-1 replication cycle starts when a virion attaches to a host cell through 
interactions between the viral envelope gp120 and the CD4 receptor on the host cells 
and subsequently, to a chemokine coreceptor (typically CCR5 or CXCR4). Coreceptor 
binding in turn induces structural changes in gp41, which extends its N-terminal fusion 
peptide into the cell membrane and triggers fusion of the viral and cellular membranes. 
Membrane fusion allows the release of the viral core into the cytoplasm, which 
subsequently disassociates to expose the viral nucleoprotein complex. The HIV RNA 
genome is then reverse transcribed into a double-stranded DNA through a series of 
RNA-dependent or DNA-dependent DNA synthesis processes. This double-stranded 
DNA forms a pre-integration complex, which is transported to the cell nucleus by the 
viral protein Integrase (Int) and integrates into the host genome. The integrated 
provirus serves as template for the transcription of viral RNAs, catalyzed partially by 
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Tat. There are two categories of HIV RNA transcripts – the unspliced RNA is 
designated for packaging into new virions, and spliced mRNA is used for production of 
viral proteins by the host translational machinery. As the new virions are assembled 
and bud from the cell membrane, the Gag and Pol polyproteins are processed to their 
functional subunits, a process called “maturation”.  
 
Figure 1-2. Genomic organization of HIV-1. Adapted from Stewart SA, et al: Human 
Immunodeficiency Virus Type 1 Vpr Induces Apoptosis through Caspase Activation. J 
Virol, Vol. 74, No. 7: 3105-3111 (2000).  
 
 
HIV-1 natural history  
On average it takes about 8 to 10 years upon HIV-1 infection for clinical 
manifestation of AIDS to develop. Based on the viral replication and host immunity 
status, the overall process can be divided into 3 stages: acute infection, clinical latency 
and systemic immune deficiency (Figure 1-3). 
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Figure 1-3. Natural history of HIV-1 infection. The whole infection course can be 
divided into primary infection, clinical latency and advanced disease according to viral 
replication status and host CD4 T lymphocyte counts. Adapted from Pantaleo G, et al: 
The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 
(1993). 
 
Acute infection 
The first stage, termed acute or primary infection, spans from the infection point 
to the point where anti-HIV antibody can be detected. During this stage, the virus 
enters the body through blood or mucosal linings, is engulfed by the local immune cells 
and transferred into regional lymph nodes, where a high concentration of CD4 T cells 
reside. HIV rapidly replicates in the lymph nodes, and gets disseminated into the 
circulation, resulting in a burst of viral load. Peak viremia is usually associated with 
clinical symptoms of seroconversion, and over a few weeks declines to a “set point”, 
which is maintained throughout the clinical latency period.  
The onset of clinical symptoms generally occurs within 2 to 6 weeks post virus-
exposure. These are nonspecific and temporary symptoms, such as fever (most 
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common), pharyngitis, skin rash, nausea and dry cough (17). For this reason, often 
times people may not seek immediate medical attention till they progress to more 
advanced stages. 
 
Clinical latency 
The second stage of HIV infection has been termed the clinical latency, during 
which patients typically do not display symptoms due to their infection. Despite the 
decline in viral load to a set point, new virions are continually produced at 109 -1010 per 
day. These virions actively infect CD4 T cells, causing a rapid turnover and eventually 
depletion of this subset in the blood, gastrointestinal tract, and lymph node (18). Once 
CD4 count falls below the clinical critical point of 200 cells/µl, the risk of opportunistic 
infections increases dramatically, and a diagnosis of AIDS is made.  
 
Advanced disease 
Before the age of highly active antiretroviral therapy (HAART), patients in the 
advanced-disease stage were likely to develop AIDS-related illnesses and die within 
two years of the AIDS diagnosis (17). When CD4 counts fall below 200 cells/µl, 
patients are susceptible to classic AIDS-related events such as Pneumocystis jirovecii 
pneumonia and Kaposi's sarcoma; in addition, diseases such as cytomegalovirus 
retinitis, CNS non-Hodgkin's lymphoma are much more likely to develop once CD4 
counts fall below 50 cells/µl (19). Furthermore, these diseases often co-exist in a host, 
making diagnosis and treatment even more challenging (17). 
 
HIV-1/AIDS treatment (HAART)  
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The first antiretroviral drug, Azido-thymidine (AZT, also known as ZDV), was 
introduced more than two decades ago. Since then a variety of antiretroviral agents 
have been developed and are widely used. Owing to the unique potency and side-
effect profiles of each drug, as well as the rapid emergence of viral drug resistance, the 
most effective strategy consists of a combination of drugs to maximize the suppressive 
effects by simultaneously targeting multiple steps in the viral life cycle. Such 
combination therapy has been termed HAART (highly active antiretroviral therapy). 
Antiretroviral drugs are typically categorized by the viral life-cycle step they 
inhibit (Figure 1-4). Although a detailed description of the various antiretroviral drugs is 
beyond the scope of this thesis, selected aspects of some of the most widely used 
drugs will be briefly discussed. 
The first step in the HIV life cycle is the attachment and fusion of the virus with 
host cell membrane. Fusion inhibitors are designed either as cellular receptor/co-
receptor antagonists that prevent the attachment of viral envelope protein gp120, or as 
peptides that inhibit post-fusion conformational changes of gp41 (17). By blocking this 
early step, these drugs effectively abrogate viral infection.  
Reverse transcription is a central step in viral replication cycle. Reverse 
transcriptase inhibitors comprise nucleoside/nucleotide analogue reverse transcriptase 
inhibitor (NRTI) and non-nucleoside reverse transcriptase inhibitor (NNRTI). The 
chemical structures of NRTI drugs often closely resemble natural nucleosides except 
that they lack a 3’-hydroxyl group on the deoxyribose moiety, which is essential for the 
reverse transcriptional elongation. NNRTIs, on the other hand, are chemicals with 
longer half-lives than the NRTIs and bind directly to the reverse transcriptase to 
interfere with its catalytic activities (17).  
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Figure 1-4. HIV life cycle. HAART regimens target a variety of viral replication steps, 
including fusion with the cell membrane (step 1), reverse transcription (step 2), 
integration (step 4), and maturation (step 7). Source: National Institute of Allergy and 
Infectious Diseases (NIAID). Http://www.niaid.nih.gov/topics/HIVAIDS/Understanding/ 
Biology/pages/hivreplicationcycle.aspx. 
 
Integration is a pivotal step in the HIV-1 life cycle, where the virus inserts the 
reverse transcribed genome into the host chromatin. Inhibiting viral replication by 
blocking the viral integrase that catalyzes this step is an attractive therapeutic strategy. 
High throughput screening has identified the 4-aryl-2,4-diketobutanoic acid inhibitors 
containing a distinct diketo acid moiety (DKA) to be an attractive approach (20). These 
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DKA compounds bind to conserved motif of integrase and inhibit its enzymatic 
activities (21).  
HIV-1 protease is responsible for the posttranslational processing of the viral 
Gag and Pol polyproteins to yield their functional subunits (22). Failure to process the 
polyprotein results in immature and non-infectious viral particles (23-25). Based on the 
structure of protease, researchers design inhibitors by substituting the scissile amid 
bond in the original sequence with hydroxyethylene dipeptide isosteres; the later 
represents a transition-state analogue that binds to HIV-1 protease with a higher 
affinity than its natural substrate (26-28). Other small-molecule protease inhibitors have 
been identified based on computer-assisted search of crystallographic databases for 
structures that would dock into the active site of the enzyme (26). 
 
Important prognostic markers  
It is critical for both prognostication and therapeutic intervention to predict the 
disease progression and outcome for HIV infection, since it features a prolonged period 
of clinical lantency. Up until now, the two prognostic factors that have yielded the most 
accurate predictions of disease progression are the CD4 lymphocyte count and the 
plasma viral load after seroconversion (29-32). In addition, quantitation of immune 
activation levels has recently emerged as a strong predictor of the disease outcome 
(33, 34).  
Immune activation reflects the “fighting” mode of the immune system and is 
crucial for pathogen clearance. That being said, over-activation of the immune system 
often results in increased susceptibility and faster turnover rate of CD4 T cells (35), as 
well as enhanced apoptosis of other players in both innate and adaptive immune 
responses (36-38). Furthermore, abnormal high immune activation leads to severe 
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disruption of the vascular endothelium and other tissues, by driving high-level, 
disorganized secretion of pro-inflammatory cytokines and chemokines (39, 40). In a 
chronic inflammatory disease such as HIV-1-infection, even in the setting of HAART, 
the damage of persistent immune activation often outweighs its benefit, and high 
activation levels (as measured by the surface expression of CD38 and/or HLA-DR) are 
consistently observed to be associated with faster disease progression (33, 34, 41, 42).  
A similar association between chronic immune activation and disease 
progression is also found in primates infected with AIDS viruses. Simian 
immunodeficiency virus (SIV) is the primate HIV-1 counterpart. It infects rhesus 
macaques and results in HIV-like syndromes; untreated animals eventually progress to 
AIDS. However, when SIV infects its natural host, the sooty mangabey, the host does 
not develop any SIV-related syndromes despite high level viremia. Interestingly, unlike 
rhesus macaques, which display massive chronic activation and enhanced activation-
induced apoptosis, sooty mangabeys exhibit minimal immune activation (43). This 
significant divergence in immune activation status is believed to contribute to the 
different disease outcomes between the two species (43). 
To better understand immune activation in HIV-1 infection, we need to know 
what is causing it. At first glance, it may appear to be the direct result of viral infection. 
However, the fact that the majority of dying CD4 cells are not productively infected 
suggests that this is not the primary reason (38, 44). A few mechanisms have been 
proposed. Firstly, HIV gene products can induce activation of lymphocytes and 
macrophages, which in turn secret pro-inflammatory cytokines (45-47). Secondly, HIV-
1-related co-infections such as CMV and EBV can contribute to the activation of the 
immune system (48-50). Thirdly, HIV-1 causes disruption of the intestinal mucosal 
barrier, which in turn leads to translocation of gut microbial products into the circulation 
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(51). Further, a recent study discovered a large number of previously undescribed 
enteric viruses in the gastrointestinal tract of SIV-infected rhesus monkeys (52). The 
activities of these viruses can contribute to intestinal leakage and systemic immune 
activation (52). In any of the situations mentioned above, cells are not productively 
activated through specific interactions between HIV antigens and the cellular T cell 
receptors (TCR). Instead, they are stimulated either by non-HIV antigens, or by 
antigen-independent mechanisms, such as surface receptor ligation, or soluble factors 
secretion. The later non-TCR-mediated, non-antigen-specific activation is termed 
bystander activation (38, 53). Indeed, the majority of dying CD4 T cells in HIV-1 
infection appear to be the uninfected “bystander” cells (38, 44). The bystander killing 
involves actions of both viral gene products such as Tat, Vpr, and Nef (54, 55), and 
also host-derived factors, including tumor necrosis factor-α, Fas ligand and TRAIL (56, 
57). These mechanisms are useful to explain the death of the cells that are not even 
entered by the virus. Recently, Doitsh and colleagues discovered an interesting 
mechanism for the post-viral-entry bystander cell death (58). Briefly, reverse 
transcription is initiated but failed to reach completion in these non-productively-
infected cells (59). The long reverse transcript intermediates accumulate stably in the 
cell (60), and are able to induce coordinated pro-apoptotic and pro-inflammatory 
responses (58).  
 
HIV-1 elite control 
HIV elite controllers (ECs), or elite suppressors, originally refer to HIV-infected 
individuals that maintain viral load under the detection limit for a prolonged period of 
time in the absence of HAART (61-63). With the advances in RNA detection 
technologies, researchers are now able to detect a single copy of HIV RNA per milliliter 
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of blood; the cut-off for elite controllers remains defined as viremia below 50 RNA 
copies/ml (64). Based on this definition, the EC subgroup consists only about 0.3% of 
the general HIV-infected population (64).  
Clinical investigations have indicated that disease progression and for HIV 
transmission is significantly delayed for patients who maintain viral load below 2,000 
copies/ml (65), and the subset of patients with viral load between 50 copies/ml and 
2,000 copies/ml is defined as “viremic controllers” (64). This viremia level serves as a 
predictor of disease outcome, and also as a goal for disease treatment or vaccine 
design.  
HIV controllers (especially elite controllers) are significantly different from 
untreated chronic progressors in a number of aspects, including but not limited to the 
facts that they have CD4 T cells with reduced susceptibility to HIV-1 (66), fully 
functional CD8 T cells targeting to conservative viral epitopes (67, 68), and potent 
antigen presenting dendritic cells (69). This indicates the complex and heterogeneous 
nature of elite controllers, and suggests that mechanisms for HIV control are 
multifactorial (70). 
As a closely related concept, persons categorized as long-term non-
progressors (LTNPs) are often studied. Unlike HIV controllers, LTNP is defined solely 
based on the clinical outcome: it refers to patients who do not show clinical evidence of 
immune deficiency in the absence of antiretroviral therapy for more than 10 years (71). 
As this definition does not take into consideration of viremia, one of the most 
fundamental driving forces of disease progression, it is sometimes less accurate in 
predicting disease outcome (72). As a matter of fact, LTNPs tend to vary widely in viral 
loads, and as high as 90% of them eventually lose their maintenance of stable CD4 cell 
counts and progress (72).  
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Mechanisms for HIV-1 control 
Representing the “functional cure” of HIV-1 infection, elite controller studies 
have been moving into the center of the HIV field. Mechanisms for the elite control 
phenotype have been extensively investigated around the areas of virus dynamics, 
host genetics, and host immune responses (62, 71).  
 
Virus dynamics 
HIV can rapidly escape from detection by the immune system, particularly from 
cytotoxic T cells (CTLs) and/or natural killer cells (NKs). However these mutations are 
often generated at the cost of reducing viral fitness, defined by how well a virus can 
replicate and survive in a particular host environment (73). It is therefore possible that 
elite controllers are capable of eliciting strong HIV-specific immune responses that 
render the virus less fit. Indeed, we discovered that recombinant viruses derived from 
EC pol sequence (encodes reverse transcriptase and integrase) featured a significantly 
reduced replication capacity than that derived from chronic progressors (74), 
suggesting an involvement of attenuated virus in the elite control phenotype. Another 
possibility along the same line is that the transmitted founder viral strain in EC is 
already weakened (75, 76). 
 
Host factors 
Because HIV-1 relies heavily on the host cellular machinery for its survival, host 
molecules involved in the viral life cycle could affect or even abrogate viral replication. 
An example involves a small host protein, p21, which was previously known to play an 
important role as a tumor-suppresor factor (77). We discovered that CD4 T cells from 
ECs were more resistant to HIV-1 infection than that of HIV-1 seronegative individuals 
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or progressors (66). Moreover, this resistance was strongly associated with an 
elevation in p21 expression (66). Further mechanistic studies demonstrate that p21 
was able to interact with and block a cycline-dependent kinase (CDK), which was 
crucial for HIV transcriptional elongation (66).  
 
Host immune response 
While HIV immune control has been primarily attributed to adaptive immunity, 
innate immunity also makes significant contribution in determining disease outcomes. 
Their individual roles are summarized in Figure 1-5. For the focus of this thesis, we will 
primarily discuss the roles of T cells in regulating the disease progression.  
 
Figure 1-5. Cross talks between innate immunity and adaptive immunity during HIV-1 
infection. 
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Figure 1-5 (continued). (a) HIV-1 infecting CD4 T cells (b) NK cell directly killing 
infected cells (c) dendritic cells secreting cytokine to boost an effective immune 
response (d) CD4 T cells helping to maintain HIV-1-specific CD8 T cell responses. (e) 
HIV-specific CTL effectively killing infected CD4 T cells. Source: Saez-Cirion, et al: HIV 
controllers: how do they tame the virus? Trends Immunol. 28(12): p. 532-40 (2007). 
 
CD8 cytotoxic T lymphocytes (CTLs) 
A number of in vivo and ex vivo experiments have established the central role 
of CD8 T cells in controlling HIV-1 infection (78). It was shown that transfer of CTLs 
provided full protection against HIV-1 challenge in mice with severe combined immune 
deficiency (SCID) (79). In rhesus macaques, transient CD8 T cell depletion resulted in 
a 100-10,000-fold increase in viral burden, and return of CD8 T cells reduced high 
viremia (80). In humans, favorable disease outcomes are consistently correlated with 
strong CD8 anti-viral activities (81, 82), including high functional avidity (83, 84), strong 
proliferative capacity (81), polyfunctionality (85, 86), strong capacity to produce 
cytotoxic proteins (81, 87, 88), preferential targeting of specific viral proteins (89, 90), 
and production of IL-21 (91). Phenotypically, HIV-1-specific CTLs from EC are 
generally more differentiated (71), less activated (49, 92) and less exhausted (93) than 
those from progressors.  
The anti-viral activities of CD8 T cells can be broadly classified into 
noncytotoxic effects (94-96), and HLA-class I- restricted cytotoxic T cell responses (82, 
85, 97, 98). The non-cytotoxic effects were first shown by Walker et al, who 
demonstrated that CD8 cells from HIV controllers were able to suppress HIV replication 
up to >90% in ex-vivo infected CD4 T cells, via secretion of soluble factors (99). In 
addition, CD8 T cells from EC were shown to directly kill infected cells without 
exogenous stimulation (82).  
Consistent with a dominant effect of HIV-1-specific CD8 T cell responses on 
HIV-1 immune control, HLA class I polymorphisms critically affect HIV disease 
17 
outcome (100, 101). Two large-scale studies have consistently shown a strong 
association between homozygosity at HLA-A/HLA-B loci and rapid disease progression 
(102, 103). A possible explanation for this finding is that heterozygotes have the ability 
to present a broader range of viral peptides, so that the time for the virus to develop an 
escape mutation is significantly longer than that for homozygotes (100). The other main 
mechanism by which HLA I may influence HIV disease outcome is through the 
expression of specific polymorphic alleles which can either grant the host “protection” 
against disease progression, or render the host more susceptible to progression. While 
HLA-B*57, and B*58 alleles are well-recognized protective HLA alleles, HLA-B*35-Px, 
B*801 and B*702 are often associated with faster disease progression. Interestingly, 
despite being one of the strongest indicators of disease outcome, the expression of a 
protective allele alone does not predict immune protection. We have consistently 
observed that certain proportions of HIV controllers with one or more protective alleles 
ultimately become progressors in our Boston HIV cohorts (66, 74). Many theories have 
been developed to explain the mechanism of protective alleles. For example, the 
protection associated with HLA-B*57 expression has been attributed to the improved 
capability of CD8 T cells to target a diverse pool of HIV-1 peptides (104, 105), to their 
improved ability to effectively inhibit virus’ escape by cross-recognizing dominant Gag 
variants (106), and to their suppression of virus production from super-infected CD4 T 
cells (98).   
 
CD4 helper cells 
In contrast to CD8 T cells, functional properties of CD4 T cells during HIV-1 
infection are more complicated and less well defined. On the one hand, CD4 T cells 
can critically contribute to optimized innate and adaptive immune responses directed 
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against HIV-1; on the other hand, activated CD4 T cells are preferentially infected by 
the virus and serve as the “fuel to burn” (107). Unambiguous definition of CD4 T cells’ 
net effect in HIV-1 infection is vital for understanding the pathogenesis of the disease, 
and for designing cell-based HIV/AIDS vaccines.  
During the acute phase of HIV-1 infection, strong CD4 T cell expansion predicts 
a low viremia set point and favorable disease outcomes (108), whereas failure to do so 
is an important indicator for HIV/AIDS progression (107).  
During the chronic latency stage, delayed disease progression has been 
correlated with enhanced proliferative capacity (90, 109), strong cytokine secretion (89) 
(109-112), strong cytotoxic effect (108), greater IL-21 production (113, 114), higher 
avidity and TCR binding affinity (115), and lower expression of immune inhibitory 
molecules of HIV-1-specific CD4 T cells (116). These functional capacities enable CD4 
T cells to directly contribute to viral inhibition, and/or help maintain effective and long-
lasting CD8 T cell and B cell responses (117, 118). Indeed, ex vivo human studies 
have shown that the depletion of HIV-1-specific CD4 T cells led to loss of the 
proliferative CD8 lymphocytes, which can be restored by adding back autologous CD4 
cells (119). Furthermore, preliminary data from the recent RV144 Thailand vaccine trial 
indicated an positive association between protection from the infection and HIV-1 
specific CD4 T cells (120). Similar correlations between SIV-specific CD4 T cells and 
disease outcomes have been observed in primate studies (121). Taken together, these 
results suggest that eliciting effective HIV-1-specific CD4 T cell responses protect the 
host from HIV-1 disease progression. However, the fact that CD4 T cells are the 
primary target cells for HIV-1, and therefore support viral replication and contribute to 
viral persistence (107), must be taken into consideration for the future design of cell-
mediated immune therapies. 
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Besides regulating the adaptive immunity, CD4 T cells also actively modulate 
the innate immune responses, mainly through secretion of cytokines. Indeed, CD4 T 
cells are further categorized into subsets based on their cytokine secretion profile and 
their implication in the immune response against different pathogens (Figure 1-6): Th1 
cells mediate pro-inflammatory responses and are characterized by predominant 
production of interferon-γ (IFN-γ) and tumor necrosis factor α (TNF-α); Th2 cells are 
associated with anti-inflammatory activity, and mainly secrete interleukin-4 (IL-4), IL-5 
and IL-13; Th17 cells produce high levels of IL-17 and stimulate inflammatory 
responses in organs and tissues infected with parasites; regulatory T (Treg) cells are 
specialized in suppressing immune responses.  
 
 
Figure 1-6. CD4 T helper cell categories based on associated transcriptional factors, 
products and functions. Source: Zhu, J. and Paul, W. E., CD4 T cells: fates, functions, 
and faults. Blood, 112(5): p. 1557-69 (2008). 
 
Regulatory T (Treg) cells 
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The recognition of pathogens by immune cells triggers a number of subsequent 
events including activation, expansion, differentiation, migration, and mediation of 
effector immune responses. The overall process is positively regulated, aiming to 
eliminate the pathogen as fast as possible. However, excessive immune activation 
causes serious damage to the cells and tissues, and is deleterious to the host. 
Therefore mechanisms have evolved to stop the inflammation after successful removal 
of the pathogen. Regulatory T cells play this important role of regulating immune 
responses. 
Regulatory T cells are a subset of CD3 T cells that are capable of suppressing 
potentially deleterious activities of conventional T cells (122). They are essential 
components of the immune system to maintain peripheral tolerance. As a result, 
significant reduction of Treg cell number or impaired functionality is frequently 
associated with autoimmune diseases or inflammatory disorders, such as type 1 
diabetes, asthma and inflammatory bowel disease (123-127). Although Treg cells are 
important for preventing excessive inflammatory reactions, they can also block 
beneficial responses by making the immune system insensitive to certain pathogens 
(128, 129), or limiting anti-tumor activities (130).  
 
Treg cell markers 
Currently most Treg cell studies have been focused on the classical 
CD25hiFoxp3+CD127loCD4+ Treg population. These Treg cells were first found in mice 
by their constitutive expression of CD25 and low expression level of CD127 (131-133). 
A few years later, a similar population of CD25+CD4+ regulatory T cells was isolated 
from peripheral blood, thymus, lymph nodes and cord blood in humans (134-138). 
Follow up studies found that the differentiation and function of these Treg cells was 
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tightly controlled by the expression of a single transcriptional factor, FoxP3 (Forkhead 
box P3) (139). The lack of FoxP3 expression was correlated with severe autoimmune 
disease in mice and in humans (140, 141); whereas ectopic expression of FoxP3 
confers strong suppressor function to naïve CD25-CD4 T cells (142, 143).  
Despite being the most important regulator, FoxP3’s expression is not exclusive 
to Treg cells (144). In addition, more markers have been identified to be co-expressed 
by CD25hiFoxP3+CD127loCD4+ T cells, including but not limited to CTLA-4 (145), 
CD62L (146), CD103 (147) and GARP (148, 149). However, none of these markers 
are necessary or sufficient to define a homogenous regulatory T cell population (150-
154).  
Most recently, novel populations of T cells with immunosuppressive properties 
have been identified. Unlike the classical ones, these non-classical Treg cells do not 
express or depend on FoxP3 to achieve suppression, but rather use other cell-
associated or soluble molecules to exert immunoregulation (153, 154). For this thesis, 
we focused on the roles of two non-classical Treg cells - HLA-G- and LAP expressing T 
cells – in HIV-1 infection.  
HLA-G is a non-classical MHC class 1b molecule, that can exist both in 
membrane-bound and soluble forms (155). It regulates both innate and adaptive 
immune responses by interacting with immune inhibitory receptors. Through these 
interactions, HLA-G can reduce the cytotoxicity of natural killer cells and CD8 T cells, in 
addition to suppress CD4 T cell alloproliferation and dendritic cell maturation (156-159). 
HLA-G’s expression is largely limited to certain tissues and organs such as placental 
trophoblastic tissues, thymus, cornea, nail matrix and pancreas under physiological 
conditions (160). However, ectopic expression of HLA-G is frequently associated with 
organ transplantation, autoimmune diseases, viral infections and cancer (161, 162). 
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Within these pathological contexts, HLA-G can either play a positive role by allowing 
better acceptance of organ graft or limiting autoimmune responses, or play a negative 
role by permitting malignant or virus-infected cells to escape from immunosurveillance. 
HLA-G’s functional properties in HIV-1 infection are not clear. 
TGF-β critically contributes to the differentiation, maintenance and function of 
natural Treg cells (163-166). Latency-associated peptide, or LAP, is a propeptide that 
covalently binds to TGF-β and keeps it in a latent status. LAP-expressing CD4 T cells 
are shown to be hypoproliferative, and suppressive of poly-clonal T cell proliferation in 
a Foxp3-independent manner (153). 
 
Mechanisms for suppression 
The general mechanisms employed by the CD25hiFoxP3+CD127loCD4+ Treg 
cells include secretion of inhibitory cytokines, cytolysis, metabolic disruption, and 
modulation of dendritic-cell maturation and function (167).  
Inhibitory cytokines, such as interleukin-10 (IL-10) and TGF-β, have been 
consistently observed to be associated with suppressive effects of classical Treg cells. 
IL-10, produced primarily by monocytes but tightly regulated by Treg cells, suppresses 
the antigen presentation and phagocytosis potency in monocytes/macrophages (168), 
as well as the Th17-cell mediated inflammation (169). In mice, a deletion in the IL-10 
gene resulted in over exuberant immune responses to the malaria parasite 
Plasmodium chabaudi (170). Moreover, these mice became susceptible to 
inflammatory bowel disease (170). In human allergy and asthma models, it was also 
suggested that IL-10 was indispensable for Treg-cell mediated disease control (171, 
172). TGF-β’s role, on the other hand, is slightly more controversial. Although cell-
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culture studies indicated that TGF-β was not necessary for Treg cells’ suppressive 
activities using a neutralizing antibody (173, 174), more evidence supported a critical 
role of the surface TGF-β in maintaining immunoregulatory properties by Treg cells, 
both in vitro and in vivo. These studies indicated that blocking TGF-β signal led to 
complete abrogation of cell-contact mediated suppression (175, 176). Moreover, TGF-
β was shown to convert naïve Foxp3- CD4 T cells to CD25+ CD4 regulatory T cells by 
inducing expression of FoxP3 (177, 178). In addition to IL-10 and TGF-β, IL-35 (a 
member of IL-12 heterodimeric cytokine family) has been recently described to be 
preferentially expressed by Treg cells, and serves to maximize their suppressive 
capacity (179). Abrogation of IL-35 severely reduced the regulatory activities of Treg 
cells, and ectopic expression conferred suppressive ability to naïve T cells (179).  
Besides secreting inhibitory cytokines, Treg cells are also able to kill target cells, 
a function that was previously thought to be limited to CTLs and NKs. Moreover, Treg 
cells express high levels of surface CD25, and are thought to cause deprivation-
induced apoptosis of targeting cells by consuming local IL-2 (180-182). Besides directly 
affecting T cells, Treg cells can also down-regulate DC function, which in turn 
influences effector T cells (183-185).  
 
Treg cells and HIV-1 infection 
Treg cells serve as a “double-edge-sword” in regulating HIV-1 disease 
progression. On the one hand, they may limit the beneficial immune responses (186, 
187); and on the other hand, they could suppress harmful, sometimes detrimental 
immune activation (188, 189). In this thesis, we focused on the dynamics of Treg 
frequencies during natural disease courses. Up to now, most reports support an 
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enhanced frequency of the classical CD25+FoxP3+CD4+ Treg cells in the peripheral 
blood during HIV infection (150, 190-192), though it is still controversial (187, 193). 
Despite different opinions on the change in relative proportions of Treg cells, it is 
generally agreed that the absolute Treg cell counts are reduced in chronic progressors 
(150, 187, 188, 192, 193). Collectively, these results suggest that HIV affects Treg cells 
to a lesser extent than conventional T cells, and that Treg cell preservation might be 
associated with a better disease outcome. Possible explanations for the relative 
preservation of Treg cells include better survival, increased proliferation, and tissue 
redistribution of this subset, as well as increased peripheral conversion from 
conventional T cells (194). 
Furthermore, we analyzed the functional impact of non-classical Treg cells on 
HIV-1 disease outcomes. For this purpose, we compared the immune activation level 
in an in vitro system in the presence and absence of Treg cells. We also evaluated 
changes, upon adding Treg cells, in several important functional aspects that are 
directly associated with HIV-1 disease outcomes. Two such factors are antigen-specific 
proliferative capacity and effector cytokine secretion (195-197). As early as in 1997, 
Rosenberg and colleagues demonstrated a direct correlation between HIV-1-specific 
CD4 T cell responses (both proliferation and Interferon–γ production) and control of 
virus replication and delayed disease progression (109). This association has been 
confirmed by several studies involving larger patient cohorts (90). CD8 proliferative 
capacity is also correlated with disease outcome: maintenance of HIV-1-specific 
proliferation was shown to be inversely associated with viremia in a large cohort study 
(198), and strong baseline HIV-1-specific CD8 proliferation was prospectively 
associated with a slow disease progression (197). These beneficial antigen-specific T 
cell proliferative responses may be influenced by Treg cells (187). In addition, Treg 
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cells may also affect production of important anti-viral cytokines, such as interferon-γ 
(IFN-γ) and interleukin-2 (IL-2) (186).  
 
Current investigations 
The classical Treg cells decline at a slower rate than conventional CD4 T cells 
during progressive HIV-1 infection, and this suggests that these cells may play an 
important role in the immune pathogenesis of HIV-1 infection. Indeed, functional data 
from previous studies have demonstrated that classical Treg cells can potently 
suppress HIV-1-specific T cell responses (186, 187), and in this way may contribute to 
the failure of achieving T cell mediated immune control of HIV-1 replication. However, 
classical Treg cells may also have beneficial effects on HIV-1 disease progression by 
reducing the deleterious consequences of HIV-1 associated immune activation (188, 
189). Recently, HLA-G- and LAP-expressing Treg cells have been identified that differ 
from classical Tregs by the lack of intracellular FoxP3 expression. However the 
numeric distribution and functional properties of either Treg population during HIV-1 
infection is not known.     
In the present study, we systematically analyzed the expression and function of 
HLA-G-and LAP-expressing Treg cells in patients with different stages of HIV-1 
disease infection. Our results indicate a profound reduction of HLA-G+ CD4 Treg cells 
in individuals with progressive HIV-1 infection that may stem from a higher 
susceptibility of these cells to HIV-1 infection, and functionally contribute to HIV-1-
associated immune over-activation.   
 
 
 
26 
References 
1. Gottlieb, M. S., Schroff, R., Schanker, H. M., Weisman, J. D., Fan, P. T., Wolf, 
R. A., and Saxon, A., Pneumocystis carinii pneumonia and mucosal candidiasis 
in previously healthy homosexual men: evidence of a new acquired cellular 
immunodeficiency. N Engl J Med, 1981. 305(24): p. 1425-31. 
 
2. Gallo, R. C., Sarin, P. S., Gelmann, E. P., Robert-Guroff, M., Richardson, E., 
Kalyanaraman, V. S., Mann, D., Sidhu, G. D., Stahl, R. E., Zolla-Pazner, S., 
Leibowitch, J., and Popovic, M., Isolation of human T-cell leukemia virus in 
acquired immune deficiency syndrome (AIDS). Science, 1983. 220(4599): p. 
865-7. 
 
3. Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., 
Gruest, J., Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., 
Rozenbaum, W., and Montagnier, L., Isolation of a T-lymphotropic retrovirus 
from a patient at risk for acquired immune deficiency syndrome (AIDS). Science, 
1983. 220(4599): p. 868-71. 
 
4. Coffin, J., Haase, A., Levy, J. A., Montagnier, L., Oroszlan, S., Teich, N., Temin, 
H., Toyoshima, K., Varmus, H., Vogt, P., and et al., Human immunodeficiency 
viruses. Science, 1986. 232(4751): p. 697. 
 
5. WHO/UNAID, 2011. 
 
6. Paul, William E., Fundamental Immunology. 2008. 
 
7. Prevention, US Centers for Disease Control and, 2011. 
 
8. Gao, F., Bailes, E., Robertson, D. L., Chen, Y., Rodenburg, C. M., Michael, S. 
F., Cummins, L. B., Arthur, L. O., Peeters, M., Shaw, G. M., Sharp, P. M., and 
Hahn, B. H., Origin of HIV-1 in the chimpanzee Pan troglodytes troglodytes. 
Nature, 1999. 397(6718): p. 436-41. 
 
9. Gao, F., Yue, L., White, A. T., Pappas, P. G., Barchue, J., Hanson, A. P., 
Greene, B. M., Sharp, P. M., Shaw, G. M., and Hahn, B. H., Human infection by 
genetically diverse SIVSM-related HIV-2 in west Africa. Nature, 1992. 
358(6386): p. 495-9. 
 
10. Marx, P. A., Li, Y., Lerche, N. W., Sutjipto, S., Gettie, A., Yee, J. A., Brotman, B. 
H., Prince, A. M., Hanson, A., Webster, R. G., and et al., Isolation of a simian 
immunodeficiency virus related to human immunodeficiency virus type 2 from a 
west African pet sooty mangabey. J Virol, 1991. 65(8): p. 4480-5. 
 
11. Pepin, J., Morgan, G., Dunn, D., Gevao, S., Mendy, M., Gaye, I., Scollen, N., 
Tedder, R., and Whittle, H., HIV-2-induced immunosuppression among 
asymptomatic West African prostitutes: evidence that HIV-2 is pathogenic, but 
less so than HIV-1. AIDS, 1991. 5(10): p. 1165-72. 
 
27 
12. Freed, E. O., HIV-1 and the host cell: an intimate association. Trends Microbiol, 
2004. 12(4): p. 170-7. 
 
13. Gottlinger, H. G., Sodroski, J. G., and Haseltine, W. A., Role of capsid 
precursor processing and myristoylation in morphogenesis and infectivity of 
human immunodeficiency virus type 1. Proc Natl Acad Sci U S A, 1989. 86(15): 
p. 5781-5. 
 
14. Jacks, T., Power, M. D., Masiarz, F. R., Luciw, P. A., Barr, P. J., and Varmus, H. 
E., Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. 
Nature, 1988. 331(6153): p. 280-3. 
 
15. Dvorin, J. D. and Malim, M. H., Intracellular trafficking of HIV-1 cores: journey to 
the center of the cell. Curr Top Microbiol Immunol, 2003. 281: p. 179-208. 
 
16. Greene, W. C. and Peterlin, B. M., Charting HIV's remarkable voyage through 
the cell: Basic science as a passport to future therapy. Nat Med, 2002. 8(7): p. 
673-80. 
 
17. Thomas C. Merigan, John G. Bartlett, Dani Bolognesi, Textbook of AIDS 
Medicine (second edition). 1999. 
 
18. Brenchley, J. M., Schacker, T. W., Ruff, L. E., Price, D. A., Taylor, J. H., 
Beilman, G. J., Nguyen, P. L., Khoruts, A., Larson, M., Haase, A. T., and Douek, 
D. C., CD4+ T cell depletion during all stages of HIV disease occurs 
predominantly in the gastrointestinal tract. J Exp Med, 2004. 200(6): p. 749-59. 
 
19. Volberding, P. A. and Deeks, S. G., Antiretroviral therapy and management of 
HIV infection. Lancet. 376(9734): p. 49-62. 
 
20. Quashie, P. K., Sloan, R. D., and Wainberg, M. A., Novel therapeutic strategies 
targeting HIV integrase. BMC Med. 10: p. 34. 
 
21. Semenova, E. A., Marchand, C., and Pommier, Y., HIV-1 integrase inhibitors: 
update and perspectives. Adv Pharmacol, 2008. 56: p. 199-228. 
 
22. Debouck, C., The HIV-1 protease as a therapeutic target for AIDS. AIDS Res 
Hum Retroviruses, 1992. 8(2): p. 153-64. 
 
23. Kohl, N. E., Emini, E. A., Schleif, W. A., Davis, L. J., Heimbach, J. C., Dixon, R. 
A., Scolnick, E. M., and Sigal, I. S., Active human immunodeficiency virus 
protease is required for viral infectivity. Proc Natl Acad Sci U S A, 1988. 85(13): 
p. 4686-90. 
 
24. McQuade, T. J., Tomasselli, A. G., Liu, L., Karacostas, V., Moss, B., Sawyer, T. 
K., Heinrikson, R. L., and Tarpley, W. G., A synthetic HIV-1 protease inhibitor 
with antiviral activity arrests HIV-like particle maturation. Science, 1990. 
247(4941): p. 454-6. 
 
28 
25. Seelmeier, S., Schmidt, H., Turk, V., and von der Helm, K., Human 
immunodeficiency virus has an aspartic-type protease that can be inhibited by 
pepstatin A. Proc Natl Acad Sci U S A, 1988. 85(18): p. 6612-6. 
 
26. Huff, J. R., HIV protease: a novel chemotherapeutic target for AIDS. J Med 
Chem, 1991. 34(8): p. 2305-14. 
 
27. Meek, T. D., Inhibitors of HIV-1 protease. J Enzyme Inhib, 1992. 6(1): p. 65-98. 
 
28. Tomasselli, A. G., Hui, J. O., Sawyer, T. K., Thaisrivongs, S., Hester, J. B., and 
Heinrikson, R. L., The evaluation of non-viral substrates of the HIV protease as 
leads in the design of inhibitors for AIDS therapy. Adv Exp Med Biol, 1991. 306: 
p. 469-82. 
 
29. Pachl, C., Todd, J. A., Kern, D. G., Sheridan, P. J., Fong, S. J., Stempien, M., 
Hoo, B., Besemer, D., Yeghiazarian, T., Irvine, B., and et al., Rapid and precise 
quantification of HIV-1 RNA in plasma using a branched DNA signal 
amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol, 1995. 8(5): p. 
446-54. 
 
30. Fahey, J. L., Taylor, J. M., Detels, R., Hofmann, B., Melmed, R., Nishanian, P., 
and Giorgi, J. V., The prognostic value of cellular and serologic markers in 
infection with human immunodeficiency virus type 1. N Engl J Med, 1990. 
322(3): p. 166-72. 
 
31. Jurriaans, S., Van Gemen, B., Weverling, G. J., Van Strijp, D., Nara, P., 
Coutinho, R., Koot, M., Schuitemaker, H., and Goudsmit, J., The natural history 
of HIV-1 infection: virus load and virus phenotype independent determinants of 
clinical course? Virology, 1994. 204(1): p. 223-33. 
 
32. Mellors, J. W., Munoz, A., Giorgi, J. V., Margolick, J. B., Tassoni, C. J., Gupta, 
P., Kingsley, L. A., Todd, J. A., Saah, A. J., Detels, R., Phair, J. P., and Rinaldo, 
C. R., Jr., Plasma viral load and CD4+ lymphocytes as prognostic markers of 
HIV-1 infection. Ann Intern Med, 1997. 126(12): p. 946-54. 
 
33. Giorgi, J. V., Liu, Z., Hultin, L. E., Cumberland, W. G., Hennessey, K., and 
Detels, R., Elevated levels of CD38+ CD8+ T cells in HIV infection add to the 
prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The 
Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic 
Syndr, 1993. 6(8): p. 904-12. 
 
34. Deeks, S. G., Kitchen, C. M., Liu, L., Guo, H., Gascon, R., Narvaez, A. B., Hunt, 
P., Martin, J. N., Kahn, J. O., Levy, J., McGrath, M. S., and Hecht, F. M., 
Immune activation set point during early HIV infection predicts subsequent 
CD4+ T-cell changes independent of viral load. Blood, 2004. 104(4): p. 942-7. 
 
35. Douek, D. C., Picker, L. J., and Koup, R. A., T cell dynamics in HIV-1 infection. 
Annu Rev Immunol, 2003. 21: p. 265-304. 
 
29 
36. Groux, H., Torpier, G., Monte, D., Mouton, Y., Capron, A., and Ameisen, J. C., 
Activation-induced death by apoptosis in CD4+ T cells from human 
immunodeficiency virus-infected asymptomatic individuals. J Exp Med, 1992. 
175(2): p. 331-40. 
 
37. Meyaard, L., Otto, S. A., Jonker, R. R., Mijnster, M. J., Keet, R. P., and 
Miedema, F., Programmed death of T cells in HIV-1 infection. Science, 1992. 
257(5067): p. 217-9. 
 
38. Finkel, T. H., Tudor-Williams, G., Banda, N. K., Cotton, M. F., Curiel, T., Monks, 
C., Baba, T. W., Ruprecht, R. M., and Kupfer, A., Apoptosis occurs 
predominantly in bystander cells and not in productively infected cells of HIV- 
and SIV-infected lymph nodes. Nat Med, 1995. 1(2): p. 129-34. 
 
39. Molina, J. M., Scadden, D. T., Byrn, R., Dinarello, C. A., and Groopman, J. E., 
Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic 
cells infected with human immunodeficiency virus. J Clin Invest, 1989. 84(3): p. 
733-7. 
 
40. Canque, B., Rosenzwajg, M., Gey, A., Tartour, E., Fridman, W. H., and 
Gluckman, J. C., Macrophage inflammatory protein-1alpha is induced by 
human immunodeficiency virus infection of monocyte-derived macrophages. 
Blood, 1996. 87(5): p. 2011-9. 
 
41. Liu, Z., Cumberland, W. G., Hultin, L. E., Kaplan, A. H., Detels, R., and Giorgi, J. 
V., CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of 
pathogenesis distinct from viral burden and immunodeficiency. J Acquir 
Immune Defic Syndr Hum Retrovirol, 1998. 18(4): p. 332-40. 
 
42. Hazenberg, M. D., Otto, S. A., van Benthem, B. H., Roos, M. T., Coutinho, R. A., 
Lange, J. M., Hamann, D., Prins, M., and Miedema, F., Persistent immune 
activation in HIV-1 infection is associated with progression to AIDS. AIDS, 2003. 
17(13): p. 1881-8. 
 
43. Silvestri, G., Sodora, D. L., Koup, R. A., Paiardini, M., O'Neil, S. P., McClure, H. 
M., Staprans, S. I., and Feinberg, M. B., Nonpathogenic SIV infection of sooty 
mangabeys is characterized by limited bystander immunopathology despite 
chronic high-level viremia. Immunity, 2003. 18(3): p. 441-52. 
 
44. Jekle, A., Keppler, O. T., De Clercq, E., Schols, D., Weinstein, M., and 
Goldsmith, M. A., In vivo evolution of human immunodeficiency virus type 1 
toward increased pathogenicity through CXCR4-mediated killing of uninfected 
CD4 T cells. J Virol, 2003. 77(10): p. 5846-54. 
 
45. Merrill, J. E., Koyanagi, Y., and Chen, I. S., Interleukin-1 and tumor necrosis 
factor alpha can be induced from mononuclear phagocytes by human 
immunodeficiency virus type 1 binding to the CD4 receptor. J Virol, 1989. 
63(10): p. 4404-8. 
 
30 
46. Rieckmann, P., Poli, G., Fox, C. H., Kehrl, J. H., and Fauci, A. S., Recombinant 
gp120 specifically enhances tumor necrosis factor-alpha production and Ig 
secretion in B lymphocytes from HIV-infected individuals but not from 
seronegative donors. J Immunol, 1991. 147(9): p. 2922-7. 
 
47. Lee, C., Liu, Q. H., Tomkowicz, B., Yi, Y., Freedman, B. D., and Collman, R. G., 
Macrophage activation through CCR5- and CXCR4-mediated gp120-elicited 
signaling pathways. J Leukoc Biol, 2003. 74(5): p. 676-82. 
 
48. Dunn, H. S., Haney, D. J., Ghanekar, S. A., Stepick-Biek, P., Lewis, D. B., and 
Maecker, H. T., Dynamics of CD4 and CD8 T cell responses to cytomegalovirus 
in healthy human donors. J Infect Dis, 2002. 186(1): p. 15-22. 
 
49. Papagno, L., Spina, C. A., Marchant, A., Salio, M., Rufer, N., Little, S., Dong, T., 
Chesney, G., Waters, A., Easterbrook, P., et al., Immune activation and CD8+ 
T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol, 2004. 
2(2): p. E20. 
 
50. Doisne, J. M., Urrutia, A., Lacabaratz-Porret, C., Goujard, C., Meyer, L., Chaix, 
M. L., Sinet, M., and Venet, A., CD8+ T cells specific for EBV, cytomegalovirus, 
and influenza virus are activated during primary HIV infection. J Immunol, 2004. 
173(4): p. 2410-8. 
 
51. Brenchley, J. M., Price, D. A., Schacker, T. W., Asher, T. E., Silvestri, G., Rao, 
S., Kazzaz, Z., Bornstein, E., Lambotte, O., Altmann, D., et al., Microbial 
translocation is a cause of systemic immune activation in chronic HIV infection. 
Nat Med, 2006. 12(12): p. 1365-71. 
 
52. Handley, S. A., Thackray, L. B., Zhao, G., Presti, R., Miller, A. D., Droit, L., 
Abbink, P., Maxfield, L. F., Kambal, A., Duan, E., et al., Pathogenic simian 
immunodeficiency virus infection is associated with expansion of the enteric 
virome. Cell. 151(2): p. 253-66. 
 
53. Bangs, S. C., Baban, D., Cattan, H. J., Li, C. K., McMichael, A. J., and Xu, X. N., 
Human CD4+ memory T cells are preferential targets for bystander activation 
and apoptosis. J Immunol, 2009. 182(4): p. 1962-71. 
 
54. Schindler, M., Munch, J., Kutsch, O., Li, H., Santiago, M. L., Bibollet-Ruche, F., 
Muller-Trutwin, M. C., Novembre, F. J., Peeters, M., Courgnaud, V., Bailes, E., 
Roques, P., Sodora, D. L., Silvestri, G., Sharp, P. M., Hahn, B. H., and 
Kirchhoff, F., Nef-mediated suppression of T cell activation was lost in a 
lentiviral lineage that gave rise to HIV-1. Cell, 2006. 125(6): p. 1055-67. 
 
55. Westendorp, M. O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., 
Walczak, H., Debatin, K. M., and Krammer, P. H., Sensitization of T cells to 
CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature, 1995. 375(6531): p. 
497-500. 
 
31 
56. Gandhi, R. T., Chen, B. K., Straus, S. E., Dale, J. K., Lenardo, M. J., and 
Baltimore, D., HIV-1 directly kills CD4+ T cells by a Fas-independent 
mechanism. J Exp Med, 1998. 187(7): p. 1113-22. 
 
57. Herbeuval, J. P., Grivel, J. C., Boasso, A., Hardy, A. W., Chougnet, C., Dolan, 
M. J., Yagita, H., Lifson, J. D., and Shearer, G. M., CD4+ T-cell death induced 
by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, 
TRAIL/DR5-mediated apoptosis. Blood, 2005. 106(10): p. 3524-31. 
 
58. Doitsh, G., Cavrois, M., Lassen, K. G., Zepeda, O., Yang, Z., Santiago, M. L., 
Hebbeler, A. M., and Greene, W. C., Abortive HIV infection mediates CD4 T cell 
depletion and inflammation in human lymphoid tissue. Cell. 143(5): p. 789-801. 
 
59. Zack, J. A., Arrigo, S. J., Weitsman, S. R., Go, A. S., Haislip, A., and Chen, I. S., 
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a 
labile, latent viral structure. Cell, 1990. 61(2): p. 213-22. 
 
60. Swiggard, W. J., O'Doherty, U., McGain, D., Jeyakumar, D., and Malim, M. H., 
Long HIV type 1 reverse transcripts can accumulate stably within resting CD4+ 
T cells while short ones are degraded. AIDS Res Hum Retroviruses, 2004. 
20(3): p. 285-95. 
 
61. Lefrere, J. J., Mariotti, M., Morand-Joubert, L., Thauvin, M., and Roudot-
Thoraval, F., Plasma human immunodeficiency virus RNA below 40 Copies/mL 
is rare in untreated persons even in the first years of infection. J Infect Dis, 
1999. 180(2): p. 526-9. 
 
62. Lambotte, O., Boufassa, F., Madec, Y., Nguyen, A., Goujard, C., Meyer, L., 
Rouzioux, C., Venet, A., and Delfraissy, J. F., HIV controllers: a homogeneous 
group of HIV-1-infected patients with spontaneous control of viral replication. 
Clin Infect Dis, 2005. 41(7): p. 1053-6. 
 
63. Deeks, S. G. and Walker, B. D., Human immunodeficiency virus controllers: 
mechanisms of durable virus control in the absence of antiretroviral therapy. 
Immunity, 2007. 27(3): p. 406-16. 
 
64. Walker, B. D., Elite control of HIV Infection: implications for vaccines and 
treatment. Top HIV Med, 2007. 15(4): p. 134-6. 
 
65. Okulicz, J. F., Marconi, V. C., Landrum, M. L., Wegner, S., Weintrob, A., 
Ganesan, A., Hale, B., Crum-Cianflone, N., Delmar, J., Barthel, V., Quinnan, G., 
Agan, B. K., and Dolan, M. J., Clinical outcomes of elite controllers, viremic 
controllers, and long-term nonprogressors in the US Department of Defense 
HIV natural history study. J Infect Dis, 2009. 200(11): p. 1714-23. 
 
66. Chen, H., Li, C., Huang, J., Cung, T., Seiss, K., Beamon, J., Carrington, M. F., 
Porter, L. C., Burke, P. S., Yang, Y., et al., CD4+ T cells from elite controllers 
resist HIV-1 infection by selective upregulation of p21. J Clin Invest. 121(4): p. 
1549-60. 
 
32 
67. Chen, H., Piechocka-Trocha, A., Miura, T., Brockman, M. A., Julg, B. D., Baker, 
B. M., Rothchild, A. C., Block, B. L., Schneidewind, A., Koibuchi, T., Pereyra, F., 
Allen, T. M., and Walker, B. D., Differential neutralization of human 
immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-
specific cytotoxic T lymphocytes. J Virol, 2009. 83(7): p. 3138-49. 
 
68. Julg, B., Williams, K. L., Reddy, S., Bishop, K., Qi, Y., Carrington, M., Goulder, 
P. J., Ndung'u, T., and Walker, B. D., Enhanced anti-HIV functional activity 
associated with Gag-specific CD8 T-cell responses. J Virol. 84(11): p. 5540-9. 
 
69. Huang, J., Burke, P. S., Cung, T. D., Pereyra, F., Toth, I., Walker, B. D., Borges, 
L., Lichterfeld, M., and Yu, X. G., Leukocyte immunoglobulin-like receptors 
maintain unique antigen-presenting properties of circulating myeloid dendritic 
cells in HIV-1-infected elite controllers. J Virol. 84(18): p. 9463-71. 
 
70. Vigneault, F., Woods, M., Buzon, M. J., Li, C., Pereyra, F., Crosby, S. D., 
Rychert, J., Church, G., Martinez-Picado, J., Rosenberg, E. S., Telenti, A., Yu, 
X. G., and Lichterfeld, M., Transcriptional profiling of CD4 T cells identifies 
distinct subgroups of HIV-1 elite controllers. J Virol. 85(6): p. 3015-9. 
 
71. Saez-Cirion, A., Pancino, G., Sinet, M., Venet, A., and Lambotte, O., HIV 
controllers: how do they tame the virus? Trends Immunol, 2007. 28(12): p. 532-
40. 
 
72. Lefrere, J. J., Morand-Joubert, L., Mariotti, M., Bludau, H., Burghoffer, B., Petit, 
J. C., and Roudot-Thoraval, F., Even individuals considered as long-term 
nonprogressors show biological signs of progression after 10 years of human 
immunodeficiency virus infection. Blood, 1997. 90(3): p. 1133-40. 
 
73. Domingo, E. and Holland, J. J., RNA virus mutations and fitness for survival. 
Annu Rev Microbiol, 1997. 51: p. 151-78. 
 
74. Brumme, Z. L., Li, C., Miura, T., Sela, J., Rosato, P. C., Brumme, C. J., Markle, 
T. J., Martin, E., Block, B. L., Trocha, A., Kadie, C. M., Allen, T. M., Pereyra, F., 
Heckerman, D., Walker, B. D., and Brockman, M. A., Reduced replication 
capacity of NL4-3 recombinant viruses encoding reverse transcriptase-
integrase sequences from HIV-1 elite controllers. J Acquir Immune Defic Syndr. 
56(2): p. 100-8. 
 
75. Chopera, D. R., Woodman, Z., Mlisana, K., Mlotshwa, M., Martin, D. P., 
Seoighe, C., Treurnicht, F., de Rosa, D. A., Hide, W., Karim, S. A., Gray, C. M., 
and Williamson, C., Transmission of HIV-1 CTL escape variants provides HLA-
mismatched recipients with a survival advantage. PLoS Pathog, 2008. 4(3): p. 
e1000033. 
 
76. Goepfert, P. A., Lumm, W., Farmer, P., Matthews, P., Prendergast, A., Carlson, 
J. M., Derdeyn, C. A., Tang, J., Kaslow, R. A., Bansal, A., Yusim, K., 
Heckerman, D., Mulenga, J., Allen, S., Goulder, P. J., and Hunter, E., 
Transmission of HIV-1 Gag immune escape mutations is associated with 
reduced viral load in linked recipients. J Exp Med, 2008. 205(5): p. 1009-17. 
33 
 
77. Abbas, T. and Dutta, A., p21 in cancer: intricate networks and multiple activities. 
Nat Rev Cancer, 2009. 9(6): p. 400-14. 
 
78. McMichael, A. J. and Rowland-Jones, S. L., Cellular immune responses to HIV. 
Nature, 2001. 410(6831): p. 980-7. 
 
79. Mosier, D. E., Human immunodeficiency virus infection of human cells 
transplanted to severe combined immunodeficient mice. Adv Immunol, 1996. 63: 
p. 79-125. 
 
80. Friedrich, T. C., Valentine, L. E., Yant, L. J., Rakasz, E. G., Piaskowski, S. M., 
Furlott, J. R., Weisgrau, K. L., Burwitz, B., May, G. E., Leon, E. J., Soma, T., 
Napoe, G., Capuano, S. V., 3rd, Wilson, N. A., and Watkins, D. I., Subdominant 
CD8+ T-cell responses are involved in durable control of AIDS virus replication. 
J Virol, 2007. 81(7): p. 3465-76. 
 
81. Migueles, S. A., Laborico, A. C., Shupert, W. L., Sabbaghian, M. S., Rabin, R., 
Hallahan, C. W., Van Baarle, D., Kostense, S., Miedema, F., McLaughlin, M., 
Ehler, L., Metcalf, J., Liu, S., and Connors, M., HIV-specific CD8+ T cell 
proliferation is coupled to perforin expression and is maintained in 
nonprogressors. Nat Immunol, 2002. 3(11): p. 1061-8. 
 
82. Saez-Cirion, A., Lacabaratz, C., Lambotte, O., Versmisse, P., Urrutia, A., 
Boufassa, F., Barre-Sinoussi, F., Delfraissy, J. F., Sinet, M., Pancino, G., and 
Venet, A., HIV controllers exhibit potent CD8 T cell capacity to suppress HIV 
infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc 
Natl Acad Sci U S A, 2007. 104(16): p. 6776-81. 
 
83. Almeida, J. R., Price, D. A., Papagno, L., Arkoub, Z. A., Sauce, D., Bornstein, 
E., Asher, T. E., Samri, A., Schnuriger, A., Theodorou, I., Costagliola, D., 
Rouzioux, C., Agut, H., Marcelin, A. G., Douek, D., Autran, B., and Appay, V., 
Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, 
polyfunctionality, and clonal turnover. J Exp Med, 2007. 204(10): p. 2473-85. 
 
84. Berger, C. T., Frahm, N., Price, D. A., Mothe, B., Ghebremichael, M., Hartman, 
K. L., Henry, L. M., Brenchley, J. M., Ruff, L. E., Venturi, V., Pereyra, F., Sidney, 
J., Sette, A., Douek, D. C., Walker, B. D., Kaufmann, D. E., and Brander, C., 
High-functional-avidity cytotoxic T lymphocyte responses to HLA-B-restricted 
Gag-derived epitopes associated with relative HIV control. J Virol. 85(18): p. 
9334-45. 
 
85. Betts, M. R., Nason, M. C., West, S. M., De Rosa, S. C., Migueles, S. A., 
Abraham, J., Lederman, M. M., Benito, J. M., Goepfert, P. A., Connors, M., 
Roederer, M., and Koup, R. A., HIV nonprogressors preferentially maintain 
highly functional HIV-specific CD8+ T cells. Blood, 2006. 107(12): p. 4781-9. 
 
86. Ferre, A. L., Hunt, P. W., Critchfield, J. W., Young, D. H., Morris, M. M., Garcia, 
J. C., Pollard, R. B., Yee, H. F., Jr., Martin, J. N., Deeks, S. G., and Shacklett, B. 
34 
L., Mucosal immune responses to HIV-1 in elite controllers: a potential correlate 
of immune control. Blood, 2009. 113(17): p. 3978-89. 
 
87. Hersperger, A. R., Pereyra, F., Nason, M., Demers, K., Sheth, P., Shin, L. Y., 
Kovacs, C. M., Rodriguez, B., Sieg, S. F., Teixeira-Johnson, L., Gudonis, D., 
Goepfert, P. A., Lederman, M. M., Frank, I., Makedonas, G., Kaul, R., Walker, B. 
D., and Betts, M. R., Perforin expression directly ex vivo by HIV-specific CD8 T-
cells is a correlate of HIV elite control. PLoS Pathog. 6(5): p. e1000917. 
 
88. Harari, A., Enders, F. B., Cellerai, C., Bart, P. A., and Pantaleo, G., Distinct 
profiles of cytotoxic granules in memory CD8 T cells correlate with function, 
differentiation stage, and antigen exposure. J Virol, 2009. 83(7): p. 2862-71. 
 
89. Pereyra, F., Addo, M. M., Kaufmann, D. E., Liu, Y., Miura, T., Rathod, A., Baker, 
B., Trocha, A., Rosenberg, R., Mackey, E., Ueda, P., Lu, Z., Cohen, D., Wrin, T., 
Petropoulos, C. J., Rosenberg, E. S., and Walker, B. D., Genetic and 
immunologic heterogeneity among persons who control HIV infection in the 
absence of therapy. J Infect Dis, 2008. 197(4): p. 563-71. 
 
90. Dyer, W. B., Zaunders, J. J., Yuan, F. F., Wang, B., Learmont, J. C., Geczy, A. 
F., Saksena, N. K., McPhee, D. A., Gorry, P. R., and Sullivan, J. S., 
Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell 
proliferative responses to p24 antigen correlate with control of viraemia and 
lack of disease progression after long-term transfusion-acquired HIV-1 infection. 
Retrovirology, 2008. 5: p. 112. 
 
91. Williams, L. D., Bansal, A., Sabbaj, S., Heath, S. L., Song, W., Tang, J., Zajac, 
A. J., and Goepfert, P. A., Interleukin-21-producing HIV-1-specific CD8 T cells 
are preferentially seen in elite controllers. J Virol. 85(5): p. 2316-24. 
 
92. Kestens, L., Vanham, G., Gigase, P., Young, G., Hannet, I., Vanlangendonck, 
F., Hulstaert, F., and Bach, B. A., Expression of activation antigens, HLA-DR 
and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS, 1992. 6(8): p. 
793-7. 
 
93. Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, 
S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al., PD-1 
expression on HIV-specific T cells is associated with T-cell exhaustion and 
disease progression. Nature, 2006. 443(7109): p. 350-4. 
 
94. Walker, C. M., Moody, D. J., Stites, D. P., and Levy, J. A., CD8+ lymphocytes 
can control HIV infection in vitro by suppressing virus replication. Science, 1986. 
234(4783): p. 1563-6. 
 
95. Walker, C. M., Erickson, A. L., Hsueh, F. C., and Levy, J. A., Inhibition of 
human immunodeficiency virus replication in acutely infected CD4+ cells by 
CD8+ cells involves a noncytotoxic mechanism. J Virol, 1991. 65(11): p. 5921-7. 
 
96. Levy, J. A., The search for the CD8+ cell anti-HIV factor (CAF). Trends 
Immunol, 2003. 24(12): p. 628-32. 
35 
 
97. Walker, B. D., Chakrabarti, S., Moss, B., Paradis, T. J., Flynn, T., Durno, A. G., 
Blumberg, R. S., Kaplan, J. C., Hirsch, M. S., and Schooley, R. T., HIV-specific 
cytotoxic T lymphocytes in seropositive individuals. Nature, 1987. 328(6128): p. 
345-8. 
 
98. Migueles, S. A., Osborne, C. M., Royce, C., Compton, A. A., Joshi, R. P., 
Weeks, K. A., Rood, J. E., Berkley, A. M., Sacha, J. B., Cogliano-Shutta, N. A., 
et al., Lytic granule loading of CD8+ T cells is required for HIV-infected cell 
elimination associated with immune control. Immunity, 2008. 29(6): p. 1009-21. 
 
99. Walker, C. M. and Levy, J. A., A diffusible lymphokine produced by CD8+ T 
lymphocytes suppresses HIV replication. Immunology, 1989. 66(4): p. 628-30. 
 
100. Carrington, M. and O'Brien, S. J., The influence of HLA genotype on AIDS. 
Annu Rev Med, 2003. 54: p. 535-51. 
 
101. Pereyra, F., Jia, X., McLaren, P. J., Telenti, A., de Bakker, P. I., Walker, B. D., 
Ripke, S., Brumme, C. J., Pulit, S. L., Carrington, M., et al., The major genetic 
determinants of HIV-1 control affect HLA class I peptide presentation. Science. 
330(6010): p. 1551-7. 
 
102. Carrington, M., Nelson, G. W., Martin, M. P., Kissner, T., Vlahov, D., Goedert, J. 
J., Kaslow, R., Buchbinder, S., Hoots, K., and O'Brien, S. J., HLA and HIV-1: 
heterozygote advantage and B*35-Cw*04 disadvantage. Science, 1999. 
283(5408): p. 1748-52. 
 
103. Tang, J., Costello, C., Keet, I. P., Rivers, C., Leblanc, S., Karita, E., Allen, S., 
and Kaslow, R. A., HLA class I homozygosity accelerates disease progression 
in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses, 
1999. 15(4): p. 317-24. 
 
104. Klein, M. R., van der Burg, S. H., Hovenkamp, E., Holwerda, A. M., Drijfhout, J. 
W., Melief, C. J., and Miedema, F., Characterization of HLA-B57-restricted 
human immunodeficiency virus type 1 Gag- and RT-specific cytotoxic T 
lymphocyte responses. J Gen Virol, 1998. 79 ( Pt 9): p. 2191-201. 
 
105. Goulder, P. J., Bunce, M., Krausa, P., McIntyre, K., Crowley, S., Morgan, B., 
Edwards, A., Giangrande, P., Phillips, R. E., and McMichael, A. J., Novel, 
cross-restricted, conserved, and immunodominant cytotoxic T lymphocyte 
epitopes in slow progressors in HIV type 1 infection. AIDS Res Hum 
Retroviruses, 1996. 12(18): p. 1691-8. 
 
106. Gillespie, G. M., Kaul, R., Dong, T., Yang, H. B., Rostron, T., Bwayo, J. J., 
Kiama, P., Peto, T., Plummer, F. A., McMichael, A. J., and Rowland-Jones, S. 
L., Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow 
progressors with B*57. AIDS, 2002. 16(7): p. 961-72. 
 
107. Douek, D. C., Brenchley, J. M., Betts, M. R., Ambrozak, D. R., Hill, B. J., 
Okamoto, Y., Casazza, J. P., Kuruppu, J., Kunstman, K., Wolinsky, S., 
36 
Grossman, Z., Dybul, M., Oxenius, A., Price, D. A., Connors, M., and Koup, R. 
A., HIV preferentially infects HIV-specific CD4+ T cells. Nature, 2002. 
417(6884): p. 95-8. 
 
108. Soghoian, D. Z., Jessen, H., Flanders, M., Sierra-Davidson, K., Cutler, S., 
Pertel, T., Ranasinghe, S., Lindqvist, M., Davis, I., Lane, K., Rychert, J., 
Rosenberg, E. S., Piechocka-Trocha, A., Brass, A. L., Brenchley, J. M., Walker, 
B. D., and Streeck, H., HIV-specific cytolytic CD4 T cell responses during acute 
HIV infection predict disease outcome. Sci Transl Med. 4(123): p. 123ra25. 
 
109. Rosenberg, E. S., Billingsley, J. M., Caliendo, A. M., Boswell, S. L., Sax, P. E., 
Kalams, S. A., and Walker, B. D., Vigorous HIV-1-specific CD4+ T cell 
responses associated with control of viremia. Science, 1997. 278(5342): p. 
1447-50. 
 
110. Younes, S. A., Yassine-Diab, B., Dumont, A. R., Boulassel, M. R., Grossman, 
Z., Routy, J. P., and Sekaly, R. P., HIV-1 viremia prevents the establishment of 
interleukin 2-producing HIV-specific memory CD4+ T cells endowed with 
proliferative capacity. J Exp Med, 2003. 198(12): p. 1909-22. 
 
111. Betts, M. R., Ambrozak, D. R., Douek, D. C., Bonhoeffer, S., Brenchley, J. M., 
Casazza, J. P., Koup, R. A., and Picker, L. J., Analysis of total human 
immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: 
relationship to viral load in untreated HIV infection. J Virol, 2001. 75(24): p. 
11983-91. 
 
112. Harari, A., Petitpierre, S., Vallelian, F., and Pantaleo, G., Skewed 
representation of functionally distinct populations of virus-specific CD4 T cells in 
HIV-1-infected subjects with progressive disease: changes after antiretroviral 
therapy. Blood, 2004. 103(3): p. 966-72. 
 
113. Chevalier, M. F., Julg, B., Pyo, A., Flanders, M., Ranasinghe, S., Soghoian, D. 
Z., Kwon, D. S., Rychert, J., Lian, J., Muller, M. I., Cutler, S., McAndrew, E., 
Jessen, H., Pereyra, F., Rosenberg, E. S., Altfeld, M., Walker, B. D., and 
Streeck, H., HIV-1-specific interleukin-21+ CD4+ T cell responses contribute to 
durable viral control through the modulation of HIV-specific CD8+ T cell function. 
J Virol. 85(2): p. 733-41. 
 
114. Yue, F. Y., Lo, C., Sakhdari, A., Lee, E. Y., Kovacs, C. M., Benko, E., Liu, J., 
Song, H., Jones, R. B., Sheth, P., Chege, D., Kaul, R., and Ostrowski, M. A., 
HIV-specific IL-21 producing CD4+ T cells are induced in acute and chronic 
progressive HIV infection and are associated with relative viral control. J 
Immunol. 185(1): p. 498-506. 
 
115. Vingert, B., Perez-Patrigeon, S., Jeannin, P., Lambotte, O., Boufassa, F., 
Lemaitre, F., Kwok, W. W., Theodorou, I., Delfraissy, J. F., Theze, J., and 
Chakrabarti, L. A., HIV controller CD4+ T cells respond to minimal amounts of 
Gag antigen due to high TCR avidity. PLoS Pathog. 6(2): p. e1000780. 
 
37 
116. Kaufmann, D. E., Kavanagh, D. G., Pereyra, F., Zaunders, J. J., Mackey, E. W., 
Miura, T., Palmer, S., Brockman, M., Rathod, A., Piechocka-Trocha, A., et al., 
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease 
progression and defines a reversible immune dysfunction. Nat Immunol, 2007. 
8(11): p. 1246-54. 
 
117. Nakanishi, Y., Lu, B., Gerard, C., and Iwasaki, A., CD8(+) T lymphocyte 
mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature, 2009. 
462(7272): p. 510-3. 
 
118. Virgin, H. W., Wherry, E. J., and Ahmed, R., Redefining chronic viral infection. 
Cell, 2009. 138(1): p. 30-50. 
 
119. Lichterfeld, M., Kaufmann, D. E., Yu, X. G., Mui, S. K., Addo, M. M., Johnston, 
M. N., Cohen, D., Robbins, G. K., Pae, E., Alter, G., Wurcel, A., Stone, D., 
Rosenberg, E. S., Walker, B. D., and Altfeld, M., Loss of HIV-1-specific CD8+ T 
cell proliferation after acute HIV-1 infection and restoration by vaccine-induced 
HIV-1-specific CD4+ T cells. J Exp Med, 2004. 200(6): p. 701-12. 
 
120. DeRosa, S, N Frahm, OD Defawe, D Carter, EP Thomas, R Smith, R Gottardo, 
N Kochar, H Janes, Y Fong, X Yu, NL Michael, JH Kim, S Rerks-Ngarm, MJ 
McElrath, The RV144 Vaccine Induced CD4+ T Cells Producing Th1 and Th2 
Cytokines with Proliferative Potential (Abstract). AIDS Vaccine, 2011. 
 
121. Gauduin, M. C., Yu, Y., Barabasz, A., Carville, A., Piatak, M., Lifson, J. D., 
Desrosiers, R. C., and Johnson, R. P., Induction of a virus-specific effector-
memory CD4+ T cell response by attenuated SIV infection. J Exp Med, 2006. 
203(12): p. 2661-72. 
 
122. Corthay, A., How do regulatory T cells work? Scand J Immunol, 2009. 70(4): p. 
326-36. 
 
123. Bassuny, W. M., Ihara, K., Sasaki, Y., Kuromaru, R., Kohno, H., Matsuura, N., 
and Hara, T., A functional polymorphism in the promoter/enhancer region of the 
FOXP3/Scurfin gene associated with type 1 diabetes. Immunogenetics, 2003. 
55(3): p. 149-56. 
 
124. Dejaco, C., Duftner, C., Grubeck-Loebenstein, B., and Schirmer, M., Imbalance 
of regulatory T cells in human autoimmune diseases. Immunology, 2006. 
117(3): p. 289-300. 
 
125. Sakaguchi, S., Naturally arising Foxp3-expressing CD25+CD4+ regulatory T 
cells in immunological tolerance to self and non-self. Nat Immunol, 2005. 6(4): p. 
345-52. 
 
126. Sakaguchi, S., Ono, M., Setoguchi, R., Yagi, H., Hori, S., Fehervari, Z., Shimizu, 
J., Takahashi, T., and Nomura, T., Foxp3+ CD25+ CD4+ natural regulatory T 
cells in dominant self-tolerance and autoimmune disease. Immunol Rev, 2006. 
212: p. 8-27. 
 
38 
127. Wildin, R. S., Smyk-Pearson, S., and Filipovich, A. H., Clinical and molecular 
features of the immunodysregulation, polyendocrinopathy, enteropathy, X 
linked (IPEX) syndrome. J Med Genet, 2002. 39(8): p. 537-45. 
 
128. Belkaid, Y., Regulatory T cells and infection: a dangerous necessity. Nat Rev 
Immunol, 2007. 7(11): p. 875-88. 
 
129. Rouse, B. T., Sarangi, P. P., and Suvas, S., Regulatory T cells in virus 
infections. Immunol Rev, 2006. 212: p. 272-86. 
 
130. Kretschmer, K., Apostolou, I., Jaeckel, E., Khazaie, K., and von Boehmer, H., 
Making regulatory T cells with defined antigen specificity: role in autoimmunity 
and cancer. Immunol Rev, 2006. 212: p. 163-9. 
 
131. Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., and Toda, M., Immunologic 
self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-
chains (CD25). Breakdown of a single mechanism of self-tolerance causes 
various autoimmune diseases. J Immunol, 1995. 155(3): p. 1151-64. 
 
132. Liu, W., Putnam, A. L., Xu-Yu, Z., Szot, G. L., Lee, M. R., Zhu, S., Gottlieb, P. 
A., Kapranov, P., Gingeras, T. R., Fazekas de St Groth, B., Clayberger, C., 
Soper, D. M., Ziegler, S. F., and Bluestone, J. A., CD127 expression inversely 
correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J 
Exp Med, 2006. 203(7): p. 1701-11. 
 
133. Seddiki, N., Santner-Nanan, B., Martinson, J., Zaunders, J., Sasson, S., Landay, 
A., Solomon, M., Selby, W., Alexander, S. I., Nanan, R., Kelleher, A., and 
Fazekas de St Groth, B., Expression of interleukin (IL)-2 and IL-7 receptors 
discriminates between human regulatory and activated T cells. J Exp Med, 
2006. 203(7): p. 1693-700. 
 
134. Taams, L. S., Smith, J., Rustin, M. H., Salmon, M., Poulter, L. W., and Akbar, A. 
N., Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated 
and apoptosis-prone population. Eur J Immunol, 2001. 31(4): p. 1122-31. 
 
135. Dieckmann, D., Plottner, H., Berchtold, S., Berger, T., and Schuler, G., Ex vivo 
isolation and characterization of CD4(+)CD25(+) T cells with regulatory 
properties from human blood. J Exp Med, 2001. 193(11): p. 1303-10. 
 
136. Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J., and Enk, A. H., 
Identification and functional characterization of human CD4(+)CD25(+) T cells 
with regulatory properties isolated from peripheral blood. J Exp Med, 2001. 
193(11): p. 1285-94. 
 
137. Taylor, P. A., Noelle, R. J., and Blazar, B. R., CD4(+)CD25(+) immune 
regulatory cells are required for induction of tolerance to alloantigen via 
costimulatory blockade. J Exp Med, 2001. 193(11): p. 1311-8. 
 
39 
138. Baecher-Allan, C., Brown, J. A., Freeman, G. J., and Hafler, D. A., 
CD4+CD25high regulatory cells in human peripheral blood. J Immunol, 2001. 
167(3): p. 1245-53. 
 
139. Fontenot, J. D., Gavin, M. A., and Rudensky, A. Y., Foxp3 programs the 
development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 
2003. 4(4): p. 330-6. 
 
140. Chatila, T. A., Blaeser, F., Ho, N., Lederman, H. M., Voulgaropoulos, C., Helms, 
C., and Bowcock, A. M., JM2, encoding a fork head-related protein, is mutated 
in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest, 2000. 
106(12): p. R75-81. 
 
141. Wildin, R. S., Ramsdell, F., Peake, J., Faravelli, F., Casanova, J. L., Buist, N., 
Levy-Lahad, E., Mazzella, M., Goulet, O., Perroni, L., Bricarelli, F. D., Byrne, G., 
McEuen, M., Proll, S., Appleby, M., and Brunkow, M. E., X-linked neonatal 
diabetes mellitus, enteropathy and endocrinopathy syndrome is the human 
equivalent of mouse scurfy. Nat Genet, 2001. 27(1): p. 18-20. 
 
142. Yagi, H., Nomura, T., Nakamura, K., Yamazaki, S., Kitawaki, T., Hori, S., 
Maeda, M., Onodera, M., Uchiyama, T., Fujii, S., and Sakaguchi, S., Crucial 
role of FOXP3 in the development and function of human CD25+CD4+ 
regulatory T cells. Int Immunol, 2004. 16(11): p. 1643-56. 
 
143. Hori, S., Nomura, T., and Sakaguchi, S., Control of regulatory T cell 
development by the transcription factor Foxp3. Science, 2003. 299(5609): p. 
1057-61. 
 
144. Wang, J., Ioan-Facsinay, A., van der Voort, E. I., Huizinga, T. W., and Toes, R. 
E., Transient expression of FOXP3 in human activated nonregulatory CD4+ T 
cells. Eur J Immunol, 2007. 37(1): p. 129-38. 
 
145. Read, S., Malmstrom, V., and Powrie, F., Cytotoxic T lymphocyte-associated 
antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory 
cells that control intestinal inflammation. J Exp Med, 2000. 192(2): p. 295-302. 
 
146. Fisson, S., Darrasse-Jeze, G., Litvinova, E., Septier, F., Klatzmann, D., Liblau, 
R., and Salomon, B. L., Continuous activation of autoreactive CD4+ CD25+ 
regulatory T cells in the steady state. J Exp Med, 2003. 198(5): p. 737-46. 
 
147. Sather, B. D., Treuting, P., Perdue, N., Miazgowicz, M., Fontenot, J. D., 
Rudensky, A. Y., and Campbell, D. J., Altering the distribution of Foxp3(+) 
regulatory T cells results in tissue-specific inflammatory disease. J Exp Med, 
2007. 204(6): p. 1335-47. 
 
148. Tran, D. Q., Andersson, J., Wang, R., Ramsey, H., Unutmaz, D., and Shevach, 
E. M., GARP (LRRC32) is essential for the surface expression of latent TGF-
beta on platelets and activated FOXP3+ regulatory T cells. Proc Natl Acad Sci 
U S A, 2009. 106(32): p. 13445-50. 
 
40 
149. Wang, R., Kozhaya, L., Mercer, F., Khaitan, A., Fujii, H., and Unutmaz, D., 
Expression of GARP selectively identifies activated human FOXP3+ regulatory 
T cells. Proc Natl Acad Sci U S A, 2009. 106(32): p. 13439-44. 
 
150. Schulze Zur Wiesch, J., Thomssen, A., Hartjen, P., Toth, I., Lehmann, C., 
Meyer-Olson, D., Colberg, K., Frerk, S., Babikir, D., Schmiedel, S., et al., 
Comprehensive analysis of frequency and phenotype of T regulatory cells in 
HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with 
progressive disease. J Virol. 85(3): p. 1287-97. 
 
151. Salomon, B. and Bluestone, J. A., Complexities of CD28/B7: CTLA-4 
costimulatory pathways in autoimmunity and transplantation. Annu Rev 
Immunol, 2001. 19: p. 225-52. 
 
152. Jago, C. B., Yates, J., Camara, N. O., Lechler, R. I., and Lombardi, G., 
Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol, 
2004. 136(3): p. 463-71. 
 
153. Gandhi, R., Farez, M. F., Wang, Y., Kozoriz, D., Quintana, F. J., and Weiner, H. 
L., Cutting edge: human latency-associated peptide+ T cells: a novel regulatory 
T cell subset. J Immunol. 184(9): p. 4620-4. 
 
154. Feger, U., Tolosa, E., Huang, Y. H., Waschbisch, A., Biedermann, T., Melms, 
A., and Wiendl, H., HLA-G expression defines a novel regulatory T-cell subset 
present in human peripheral blood and sites of inflammation. Blood, 2007. 
110(2): p. 568-77. 
 
155. Carosella, E. D., Favier, B., Rouas-Freiss, N., Moreau, P., and Lemaoult, J., 
Beyond the increasing complexity of the immunomodulatory HLA-G molecule. 
Blood, 2008. 111(10): p. 4862-70. 
 
156. Rouas-Freiss, N., Goncalves, R. M., Menier, C., Dausset, J., and Carosella, E. 
D., Direct evidence to support the role of HLA-G in protecting the fetus from 
maternal uterine natural killer cytolysis. Proc Natl Acad Sci U S A, 1997. 94(21): 
p. 11520-5. 
 
157. Lila, N., Rouas-Freiss, N., Dausset, J., Carpentier, A., and Carosella, E. D., 
Soluble HLA-G protein secreted by allo-specific CD4+ T cells suppresses the 
allo-proliferative response: a CD4+ T cell regulatory mechanism. Proc Natl 
Acad Sci U S A, 2001. 98(21): p. 12150-5. 
 
158. Riteau, B., Rouas-Freiss, N., Menier, C., Paul, P., Dausset, J., and Carosella, E. 
D., HLA-G2, -G3, and -G4 isoforms expressed as nonmature cell surface 
glycoproteins inhibit NK and antigen-specific CTL cytolysis. J Immunol, 2001. 
166(8): p. 5018-26. 
 
159. Wiendl, H., Mitsdoerffer, M., Hofmeister, V., Wischhusen, J., Weiss, E. H., 
Dichgans, J., Lochmuller, H., Hohlfeld, R., Melms, A., and Weller, M., The non-
classical MHC molecule HLA-G protects human muscle cells from immune-
41 
mediated lysis: implications for myoblast transplantation and gene therapy. 
Brain, 2003. 126(Pt 1): p. 176-85. 
 
160. Carosella, E. D., Moreau, P., Lemaoult, J., and Rouas-Freiss, N., HLA-G: from 
biology to clinical benefits. Trends Immunol, 2008. 29(3): p. 125-32. 
 
161. Baricordi, O. R., Stignani, M., Melchiorri, L., and Rizzo, R., HLA-G and 
inflammatory diseases. Inflamm Allergy Drug Targets, 2008. 7(2): p. 67-74. 
 
162. Carosella, E. D., Moreau, P., Aractingi, S., and Rouas-Freiss, N., HLA-G: a 
shield against inflammatory aggression. Trends Immunol, 2001. 22(10): p. 553-
5. 
 
163. Coombes, J. L., Siddiqui, K. R., Arancibia-Carcamo, C. V., Hall, J., Sun, C. M., 
Belkaid, Y., and Powrie, F., A functionally specialized population of mucosal 
CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic 
acid-dependent mechanism. J Exp Med, 2007. 204(8): p. 1757-64. 
 
164. Fahlen, L., Read, S., Gorelik, L., Hurst, S. D., Coffman, R. L., Flavell, R. A., and 
Powrie, F., T cells that cannot respond to TGF-beta escape control by 
CD4(+)CD25(+) regulatory T cells. J Exp Med, 2005. 201(5): p. 737-46. 
 
165. Gorelik, L. and Flavell, R. A., Abrogation of TGFbeta signaling in T cells leads 
to spontaneous T cell differentiation and autoimmune disease. Immunity, 2000. 
12(2): p. 171-81. 
 
166. Marie, J. C., Letterio, J. J., Gavin, M., and Rudensky, A. Y., TGF-beta1 
maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory 
T cells. J Exp Med, 2005. 201(7): p. 1061-7. 
 
167. Vignali, D. A., Collison, L. W., and Workman, C. J., How regulatory T cells work. 
Nat Rev Immunol, 2008. 8(7): p. 523-32. 
 
168. Sabat, R., Grutz, G., Warszawska, K., Kirsch, S., Witte, E., Wolk, K., and 
Geginat, J., Biology of interleukin-10. Cytokine Growth Factor Rev. 21(5): p. 
331-44. 
 
169. Chaudhry, A., Samstein, R. M., Treuting, P., Liang, Y., Pils, M. C., Heinrich, J. 
M., Jack, R. S., Wunderlich, F. T., Bruning, J. C., Muller, W., and Rudensky, A. 
Y., Interleukin-10 signaling in regulatory T cells is required for suppression of 
Th17 cell-mediated inflammation. Immunity. 34(4): p. 566-78. 
 
170. Li, C., Corraliza, I., and Langhorne, J., A defect in interleukin-10 leads to 
enhanced malarial disease in Plasmodium chabaudi chabaudi infection in mice. 
Infect Immun, 1999. 67(9): p. 4435-42. 
 
171. Hawrylowicz, C. M. and O'Garra, A., Potential role of interleukin-10-secreting 
regulatory T cells in allergy and asthma. Nat Rev Immunol, 2005. 5(4): p. 271-
83. 
 
42 
172. Joetham, A., Takeda, K., Taube, C., Miyahara, N., Matsubara, S., Koya, T., 
Rha, Y. H., Dakhama, A., and Gelfand, E. W., Naturally occurring lung 
CD4(+)CD25(+) T cell regulation of airway allergic responses depends on IL-10 
induction of TGF-beta. J Immunol, 2007. 178(3): p. 1433-42. 
 
173. Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., 
Shimizu, J., and Sakaguchi, S., Immunologic self-tolerance maintained by 
CD25+CD4+ naturally anergic and suppressive T cells: induction of 
autoimmune disease by breaking their anergic/suppressive state. Int Immunol, 
1998. 10(12): p. 1969-80. 
 
174. Piccirillo, C. A., Letterio, J. J., Thornton, A. M., McHugh, R. S., Mamura, M., 
Mizuhara, H., and Shevach, E. M., CD4(+)CD25(+) regulatory T cells can 
mediate suppressor function in the absence of transforming growth factor beta1 
production and responsiveness. J Exp Med, 2002. 196(2): p. 237-46. 
 
175. Nakamura, K., Kitani, A., and Strober, W., Cell contact-dependent 
immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell 
surface-bound transforming growth factor beta. J Exp Med, 2001. 194(5): p. 
629-44. 
 
176. Green, E. A., Gorelik, L., McGregor, C. M., Tran, E. H., and Flavell, R. A., 
CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-
beta-TGF-beta receptor interactions in type 1 diabetes. Proc Natl Acad Sci U S 
A, 2003. 100(19): p. 10878-83. 
 
177. Chen, W., Jin, W., Hardegen, N., Lei, K. J., Li, L., Marinos, N., McGrady, G., 
and Wahl, S. M., Conversion of peripheral CD4+CD25- naive T cells to 
CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor 
Foxp3. J Exp Med, 2003. 198(12): p. 1875-86. 
 
178. Fantini, M. C., Becker, C., Monteleone, G., Pallone, F., Galle, P. R., and 
Neurath, M. F., Cutting edge: TGF-beta induces a regulatory phenotype in 
CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J 
Immunol, 2004. 172(9): p. 5149-53. 
 
179. Collison, L. W., Workman, C. J., Kuo, T. T., Boyd, K., Wang, Y., Vignali, K. M., 
Cross, R., Sehy, D., Blumberg, R. S., and Vignali, D. A., The inhibitory cytokine 
IL-35 contributes to regulatory T-cell function. Nature, 2007. 450(7169): p. 566-
9. 
 
180. Thornton, A. M. and Shevach, E. M., CD4+CD25+ immunoregulatory T cells 
suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 
production. J Exp Med, 1998. 188(2): p. 287-96. 
 
181. de la Rosa, M., Rutz, S., Dorninger, H., and Scheffold, A., Interleukin-2 is 
essential for CD4+CD25+ regulatory T cell function. Eur J Immunol, 2004. 34(9): 
p. 2480-8. 
 
43 
182. Pandiyan, P., Zheng, L., Ishihara, S., Reed, J., and Lenardo, M. J., 
CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated 
apoptosis of effector CD4+ T cells. Nat Immunol, 2007. 8(12): p. 1353-62. 
 
183. Oderup, C., Cederbom, L., Makowska, A., Cilio, C. M., and Ivars, F., Cytotoxic 
T lymphocyte antigen-4-dependent down-modulation of costimulatory 
molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated 
suppression. Immunology, 2006. 118(2): p. 240-9. 
 
184. Serra, P., Amrani, A., Yamanouchi, J., Han, B., Thiessen, S., Utsugi, T., 
Verdaguer, J., and Santamaria, P., CD40 ligation releases immature dendritic 
cells from the control of regulatory CD4+CD25+ T cells. Immunity, 2003. 19(6): 
p. 877-89. 
 
185. Cederbom, L., Hall, H., and Ivars, F., CD4+CD25+ regulatory T cells down-
regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol, 
2000. 30(6): p. 1538-43. 
 
186. Aandahl, E. M., Michaelsson, J., Moretto, W. J., Hecht, F. M., and Nixon, D. F., 
Human CD4+ CD25+ regulatory T cells control T-cell responses to human 
immunodeficiency virus and cytomegalovirus antigens. J Virol, 2004. 78(5): p. 
2454-9. 
 
187. Kinter, A. L., Hennessey, M., Bell, A., Kern, S., Lin, Y., Daucher, M., Planta, M., 
McGlaughlin, M., Jackson, R., Ziegler, S. F., and Fauci, A. S., CD25(+)CD4(+) 
regulatory T cells from the peripheral blood of asymptomatic HIV-infected 
individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses 
in vitro and are associated with favorable clinical markers of disease status. J 
Exp Med, 2004. 200(3): p. 331-43. 
 
188. Eggena, M. P., Barugahare, B., Jones, N., Okello, M., Mutalya, S., Kityo, C., 
Mugyenyi, P., and Cao, H., Depletion of regulatory T cells in HIV infection is 
associated with immune activation. J Immunol, 2005. 174(7): p. 4407-14. 
 
189. Karlsson, I., Malleret, B., Brochard, P., Delache, B., Calvo, J., Le Grand, R., 
and Vaslin, B., Suppressive activity of regulatory T cells correlates with high 
CD4(+) T-cell counts and low T-cell activation during chronic simian 
immunodeficiency virus infection. AIDS. 25(5): p. 585-93. 
 
190. Bi, X., Suzuki, Y., Gatanaga, H., and Oka, S., High frequency and proliferation 
of CD4+ FOXP3+ Treg in HIV-1-infected patients with low CD4 counts. Eur J 
Immunol, 2009. 39(1): p. 301-9. 
 
191. Chase, A. J., Yang, H. C., Zhang, H., Blankson, J. N., and Siliciano, R. F., 
Preservation of FoxP3+ regulatory T cells in the peripheral blood of human 
immunodeficiency virus type 1-infected elite suppressors correlates with low 
CD4+ T-cell activation. J Virol, 2008. 82(17): p. 8307-15. 
 
192. Presicce, P., Orsborn, K., King, E., Pratt, J., Fichtenbaum, C. J., and Chougnet, 
C. A., Frequency of circulating regulatory T cells increases during chronic HIV 
44 
infection and is largely controlled by highly active antiretroviral therapy. PLoS 
One. 6(12): p. e28118. 
 
193. Jiao, Y., Fu, J., Xing, S., Fu, B., Zhang, Z., Shi, M., Wang, X., Zhang, J., Jin, L., 
Kang, F., Wu, H., and Wang, F. S., The decrease of regulatory T cells 
correlates with excessive activation and apoptosis of CD8+ T cells in HIV-1-
infected typical progressors, but not in long-term non-progressors. Immunology, 
2009. 128(1 Suppl): p. e366-75. 
 
194. Moreno-Fernandez, M. E., Presicce, P., and Chougnet, C. A., Homeostasis and 
Function of Regulatory T Cells in HIV/SIV Infection. J Virol. 86(19): p. 10262-9. 
 
195. Porichis, F. and Kaufmann, D. E., HIV-specific CD4 T cells and immune control 
of viral replication. Curr Opin HIV AIDS. 6(3): p. 174-80. 
 
196. Theze, J., Chakrabarti, L. A., Vingert, B., Porichis, F., and Kaufmann, D. E., HIV 
controllers: a multifactorial phenotype of spontaneous viral suppression. Clin 
Immunol. 141(1): p. 15-30. 
 
197. McKinnon, L. R., Kaul, R., Kimani, J., Nagelkerke, N. J., Wachihi, C., Fowke, K. 
R., Ball, T. B., and Plummer, F. A., HIV-specific CD8+ T-cell proliferation is 
prospectively associated with delayed disease progression. Immunol Cell Biol. 
90(3): p. 346-51. 
 
198. Day, C. L., Kiepiela, P., Leslie, A. J., van der Stok, M., Nair, K., Ismail, N., 
Honeyborne, I., Crawford, H., Coovadia, H. M., Goulder, P. J., Walker, B. D., 
and Klenerman, P., Proliferative capacity of epitope-specific CD8 T-cell 
responses is inversely related to viral load in chronic human immunodeficiency 
virus type 1 infection. J Virol, 2007. 81(1): p. 434-8. 
 
 
 
 
 
45 
Chapter 2 
 
 
 
Comprehensive characterization of HLA-G-
expressing regulatory T cells  
in HIV-1 infection 
 
 
 
46 
Introduction 
Several Treg populations identified recently differ from classical 
CD25hiCD127loFoxP3+ Treg cells by the lack of intracellular expression of FoxP3. 
One group of such non-classical Treg cells is defined by the surface expression of 
human leukocyte antigen (HLA-G) (1). HLA-G represents a non-classical major 
histocompatibility complex (MHC)-1b. It differs from the classical MHCs in the 
following aspects:  
1) Low polymorphisms. While classical HLA-ABCs have hundreds of 
isoforms, HLA-G’s primary transcript yields only seven protein isoforms, including 
both membrane-bound (HLA-G1, G2, G3, G4) and soluble proteins (HLA-G5, G6, 
G7). Among these, HLA-G1 and HLA-G5 are the dominant isoforms in expression 
and function (2), and are the focus of most HLA-G studies as well as this thesis.   
2) Limited expression profile. While classical HLAs are expressed by cells 
and tissues throughout the body, HLA-G expression is largely restricted to placental 
trophoblastic tissues in healthy individuals (3). However under pathological 
conditions, such as autoimmune diseases, cancer and transplantation, enhanced or 
ectopic expression of HLA-G can be detected on T cells, monocytes and dendritic 
cells (1).  
3) Distinctive functionality. Instead of promoting antigen presentation and 
T cell priming which is the primary function of classical HLAs, HLA-G is more 
involved in an immunoregulatory role (1). HLA-G+ Treg cells can suppress T cell 
activation in a contact independent manner, and their regulatory effects are 
reversible following neutralization with HLA-G blocking antibodies (4).  
HLA-G interacts primarily with immune inhibitory receptors, such as 
leukocyte immunoglobulin-like receptor subfamily (LILRB1, LILRB2), and killer cell 
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immunoglobulin-like receptors (KIR2DL4) (2). LILRB1 has a wide presence in all 
myeloid and lymphoid cells (5), while LILRB2 is restricted to myeloid lineage (6). 
KIR2DL4 is mainly found in CD56hi NK cells and some T cell lines (7, 8).  
Previous reports suggested that the proportion of HLA-G expressing 
lymphocytes was increased during HIV-1 infection (9), however, such investigations 
were conducted in unselected populations of HIV-1 positive persons, and did not 
address the functional role of HLA-G positive T cells during different stages of HIV-
1 disease progression. 
In the present study, we have systematically analyzed the expression and 
function of HLA-G-expressing Treg cells in patients with different stages of HIV-1 
infection. Our results indicate a profound reduction of HLA-G+ Treg cells in 
individuals with progressive HIV-1 disease that may stem from a higher 
susceptibility of these cells to HIV-1 infection, and functionally contribute to HIV-1-
associated immune overactivation.   
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Materials and Methods 
Study participants 
HIV-1-infected patients and seronegative individuals were recruited 
according to protocols approved by the Institutional Review Board of the 
Massachusetts General Hospital in Boston. Samples of mononuclear cells extracted 
from lymph nodes and peripheral blood were obtained from HIV-1 infected patients 
recruited at the University of Hamburg (Germany) according to a protocol approved 
by the local Ethics Committee.  
We have included in the study 5 patient groups with various status of HIV 
infection: 22 patients with primary infection and seroconversion within 3 months 
prior to recruitment (acutely infected patients), 28 treatment-naïve HIV-1 infected 
individuals with chronic progressive infection (progressors), 26 HIV-1 infected 
persons successfully treated with highly active antiretroviral therapy (HAART-
treated), 24 patients with spontaneous control of HIV-1 replication (controllers), and 
26 non-HIV-infected healthy individuals (HIV negative).  
Among acutely-infected patients, the viral load ranges from 36,600 to 
2,790,000 copies/ml, with a median of 99,900 copies/ml; CD4 T cell count varies 
from 265 to 1047/µl with a median of 475/µl. For chronic progressors, the viremia 
varies from 20,187 to 685,000 copies/ml, with a median of 48,215 copies/ml; CD4 T 
cell count varies from 204 to 652/µl, with a median of 396/µl. As for HAART-treated 
patients, all of them have viremia <50 copies/ml; CD4 T cell count ranges from 242 
to 1493/µl with a median of 402/µl. For controllers, the viral load <1,000 copies/ml, 
and CD4 T cell count varies from 347 to 1879/µl, with a median of 924/µl. 
 
Immunophenotypic analysis 
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Peripheral blood mononuclear cell (PBMC) were isolated from whole blood 
using Ficoll density centrifugation. Lymph node mononuclear cell (LNMC) were 
extracted from freshly-excised lymph node samples according to routine procedures 
(10). LNMC or PBMC were stained with LIVE/DEAD cell viability dye (Invitrogen) 
and monoclonal antibodies directed against CD4, CD25, CD127, CD45RA, CCR7 
(BD Biosciences), CD57 and PD-1 (Biolegend), CD8 (Invitrogen), HLA-G (clone 
MEM-G/9, Abcam), and when indicated, LILRB1 (clone HP-F1, ebioscience). After 
incubation for 20 minutes at room temperature, cells were fixed with PBS containing 
0.5% fetal calf serum and 1% formaldehyde. Antigen-specific staining was done by 
pre-incubating HIV-, CMV-, EBV-, or influenza-specific class I tetramer or pentamer 
with PBMCs on ice for 30min, washing away unbounded tetramer, followed by a 
regular surface staining. 
For FoxP3 intracellular staining, anti-human FoxP3 Alexa Fluor 647 
(ebioscience) was used with foxp3 staining buffer set (ebioscience) per 
manufacturer’s instruction. Briefly, 1*106 PBMCs were stained by a panel of surface 
markers including anti-CD3 (PE-Cy7), anti-CD4 (Alexa-Fluro700), anti-CD8 (Pacific 
Blue), anti-CD25 (PE-Cy5), anti-HLA-G (PE) and cell viability dye. After 20 min 
incubation at room temperature, cells were washed by PBS then by staining buffer, 
and incubated in fixation/permeabilization buffer at room temperature for 30 min. 
After being fully permeabilized, cells were washed once by staining buffer and twice 
by permeabilization buffer, and stained with Foxp3-Alexa Fluro 647 for 30 min at 
room temperature. They were then washed twice with permeabilization buffer and 
resuspended in staining buffer for flow cytometry analysis. Cells were acquired on 
LSR Fortessa™ Cell Analyzer (BD Biosciences) using DiVA software. Data were 
analyzed using FlowJo software (Tree Star).   
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Western blots  
CD3 T cells were negatively isolated from HIV seronegative donors. To 
isolate HLA-G+ cells, samples were incubated with PE anti-HLA-G antibody (clone 
MEM-G/9) for 30 min on ice, followed by immunomagnetic depletion of HLA-G using 
anti-PE magnetic beads according to the manufacturer’s protocol (Miltenyi). Cells 
bound to the column and in the flow through were collected as HLA-G+ and HLA-G- 
portion, respectively. Equal amounts of HLA-G+ and HLA-G- cells were cultured in 
RPMI 1640 medium supplemented with 2 mM l-glutamine, 50 U/ml penicillin, 50 
µg/ml streptomycin, 10 mM Hepes, 10% heat-inactivated FCS and 50U/ml IL-2, for 
a period of 4 days. Supernatant and cell lysate were collected.  
Equal amounts of supernatant or cell lysate were subjected to SDS-PAGE 
(Life Technologies), electroblotted, incubated with HLA-G antibodies (clone 4H84, 
Abcam) in 5%-milk PBS, followed by visualization with horseradish peroxidase 
(HRP)-labeled secondary antibodies and enhanced chemiluminescence (ECL) 
detection reactions (Amersham Biosciences) according to standard protocols. 
 
Cell isolation and sorting 
CD4 or CD8 T cells were isolated using a negative cell purification kit 
(Stemcell), according to the manufacturer’s instructions. Cell purity was > 95%. 
Subsequently, fluorescence activated cell sorting was used to divide bulk CD4 T 
cells into three subgroups: HLA-G- CD25hi CD4 T cells, HLA-G+ CD25- CD4 T cells, 
and HLA-G- CD25- CD4 T cells. For this purpose, CD4 cells were labeled with 
respective monoclonal antibodies and viability dye, washed, and sorted on a 
FACSAria instrument (BD Biosciences) at 70 pounds per square inch. For isolation 
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of CD8 Treg subsets, purified bulk CD8 T cells were sorted into three T cell subsets: 
HLA-G+ CD25- CD8 T cells, CD25hi CD28- CD8 T cells and a control cell population 
of HLA-G- CD25- CD8 T cells, using similar sorting conditions.   
 
Proliferation Assay 
Isolated PBMCs from HIV-1 infected individuals were stained with 0.25 µM 
carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes) and mixed with 
sorted autologous Treg populations or control T cells without regulatory activity at 
ratios of 4:1. Afterwards, cells were stimulated with a pool of overlapping peptides 
spanning the clade B consensus sequences of HIV-1 gag (2µg/ml per peptide), a 
pool of overlapping peptides spanning the entire sequence of human CMV pp65 
(2µg/ml per peptide), or PHA (10µg/ml). After incubation for 6 days in RPMI 1640 
medium supplemented with 2 mM l-glutamine, 50 U/ml penicillin, 50 µg/ml 
streptomycin, 10 mM Hepes, and 10% heat-inactivated FCS, cells were washed, 
stained with viability dye, CD4 and CD8 antibodies, fixed and acquired on a LSR 
Fortessa flow cytometer. Suppression of T cell proliferation by Tregs was calculated 
as: (T cell proliferation (%) in the non-Treg co-culture – T cell proliferation (%) in the 
Treg co-culture)/T cell proliferation (%) in the non-Treg co-culture. 
 
Intracellular Cytokine Staining 
Purified CD3 T responder cells from HIV-1 patients were stained with CFSE 
as described above and subsequently mixed with sorted autologous Treg 
populations or control CD4 T cells at a ratio of 2:1. Cells were then stimulated with a 
pool of overlapping peptides spanning HIV-1 gag (2µg/ml per peptide) in the 
presence of antibodies directed against CD28 and CD49d (BD Biosciences, 2µg/ml). 
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Cells were incubated at 37°C for 6h, and brefeldin A (BD Biosciences) was added at 
5µg/ml after the first hour of incubation. Afterwards, cells were stained with viability 
dye and antibodies against CD4 and CD8, fixed and permeabilized using a 
commercial kit (Caltag), and subjected to intracellular cytokine staining with 
monoclonal antibodies against interferon-γ (IFN-γ) and inleukin-2 (IL-2) (Becton 
Dickinson). Following final washes, cells were acquired on a LSR Fortessa 
instrument. The proportion of IFN-γ+ or IL-2+ CD4 and CD8 T cells was determined 
after gating on CD3+ CFSE+ responder T cells, using FlowJo software.  
 
Assessment of bystander activation 
Purified CD3+ responder T cells from healthy individuals were mixed with 
sorted autologous Treg populations or autologous control CD4 T cells without 
regulatory activities at a ratio of 2:1. Following stimulation with Staphylococcal 
enterotoxin B (SEB, 5mg/ml, kindly provided by Dr. Eric J. Sundberg, University of 
Maryland), cells were incubated at 37°C for 4 days. Afterwards, cells were stained 
with antibodies against CD4, CD8, CD38, HLA-DR, and Vβ13.1 and viability dye 
before being subjected to flow cytometric acquisition on a LSR Fortessa instrument. 
The surface expression of activation markers in responder T cells was analyzed 
after gating on CD3+ events. Treg-dependent suppression of bystander activation 
was calculated as: (CD38/HLA-DR-expressing T cells (%) in the non-Treg co-culture 
– CD38/HLA-DR-expressing T cells in the Treg co-culture)/CD38/HLA-DR-
expressing T cells (%) in the non-Treg co-culture. For some experiments, T cells 
were stimulated by SEB for 4 days, and LILRB1 (clone HP-F1) expression was 
assessed on day 0, 1 and 4.  
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Virus production 
GFP-encoding X4-tropic NL4-3 and R5-tropic Ba-L HIV-1 plasmid, as well as 
HIV vector, were kindly provided by Drs. Nicholas Manel and Dan Littman, New 
York University, New York, NY (11).  
Viral particles were produced by transfecting 293T cells with the respective 
HIV-1 plasmids (pCG-VSV-G was added for the single-round HIV vector), using 
TransIT-293 (Mirus) in OptiMEM following the manufacturer’s instructions. Briefly, 
293 T cells were seeded 24h prior to transfection in 10-cm plates. On the day of 
transfection, 45 µl TransIT – 293 reagent was added to 1ml OptiMEM in a sterile 
plastic tube, mixed and incubated at room temperature for 15 min. 15µg DNA was 
then added and incubated for another 30 min. Excess medium was removed from 
the plate and the TransIT-293/DNA mixture was added drop by drop to the cells. 
Gentle rocking of the dish was done to allow even distribution. Supernatants 
containing infectious retroviruses were harvested 48 hours after transfection, 
centrifuged, and stored at –80°C. Viral stock was treated with DNase I (30U/ml, 
Invitrogen) for 1 hour at room temperature before using. 
 
Susceptibility assessment 
CD4 T cells were stimulated in RPMI 1640 medium supplemented with 2 mM 
l-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, 10 mM Hepes, 10% heat-
inactivated FCS, 50U/ml IL-2, and anti-CD3/CD8 bi-specific antibodies (0.5mg/ml). 
On day 5, cells were infected with X4 (MOI=0.02) or R5-tropic (MOI=0.07) viral 
strains for 4 h, or with VSV-G vector (MOI=0.02) for 2h at 37°C. After two washes, 
cells were resuspended in warm medium and plated at 5 x 105 cells per well in 24-
well plates. Cells were fed with fresh warm medium on day 2 for X4 and R5 virus. 
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On day 2 (VSV-G) or day 4 (X4, R5), harvested and stained the cells with antibodies 
against CD3, CD4, HLA-G, CCR5, CXCR4 and viability dye, and applied to a LSR 
Fortessa instrument.  
For infection of quiescent cells, negatively-selected CD4 T cells with a purity 
of >98% were directly infected with HIV-1 vectors at MOI=0.01, X4 strain at 
MOI=0.005 and R5 strain at MOI=0.001; after in vitro culture for 96h in the absence 
of exogenous IL-2, cells were analyzed using the same staining panel by flow 
cytometric assessment.  
 
Statistical analysis 
Data are expressed as mean and standard deviation/standard error, or as box 
and whisker plots indicating the median, the 25% and 75% percentile and the minimum 
and maximum of all data. Differences between different cohorts or different 
experimental conditions were tested for statistical significance using Mann-Whitney U 
test, paired T test or one-way ANOVA, followed by post-hoc analysis using Tukey’s 
multiple comparison test, as appropriate. Spearman correlation was used to assess the 
association between two variables. A p-value of 0.05 was considered significant.  
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Results 
Reduced frequency of HLA-G+ Treg cells in progressive HIV-1 infection  
Investigations of T cells with regulatory properties in HIV-1 infection have so 
far been mostly limited to classical, CD25+ and/or FoxP3 expressing Treg subset. 
To analyze the role of alternative, non-classical Treg populations in patients infected 
with HIV-1, we focused on the recently described population of Treg cells defined by 
surface expression of HLA-G (1). These cells do not express FoxP3 or CD25 
(Figure 2-1), and are phenotypically and functionally distinct from classical Treg (1, 
4). To analyze these cells in HIV-1 infection, we used flow cytometry to determine 
the relative and absolute numbers of HLA-G-positive CD4 and CD8 T cells in 
patients with primary HIV-1 infection and seroconversion within 3 months, 
treatment-naïve HIV-1 infected individuals with chronic progressive infection, HIV-1 
infected persons successfully treated with HAART, as well as patients with 
spontaneous control of HIV-1 replication. A cohort of HIV-1 negative persons was 
recruited for control purposes.   
Consistent with prior reports (12), we observed that relative proportions of 
classical CD25hi CD127low CD4 Treg were increased in progressive HIV-1 infection, 
while absolute Treg numbers were decreased (Figure 2-2); no correlations were 
found between frequency or absolute count of Treg cells and levels of immune 
activation (Figure 2-3).  
In contrast, we observed that the proportions and absolute numbers of HLA-
G expressing CD4 T cells were lowest in HIV-1 progressors, while no significant 
differences were found between the proportions of HLA-G+ CD4 T cells in any of the 
other HIV-1 patient cohorts (Figure 2-4, 2-5). The relative frequency of HLA-G 
expressing CD8 T cells was lower in all HIV-1 infected patient populations 
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compared 
 
 
Figure 2-1. Co-expression of HLA-G with CD25 and FoxP3 in patients with different 
HIV-1 stages and healthy individuals. Co-expression of CD25 with FoxP3 is shown as 
a control of the staining.  
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Figure 2-2. Relative proportions and absolute counts of classical CD25hiCD127lo CD4 
Treg cells in indicated study populations. *:p<0.05; **: p<0.01; ***: p<0.001. 
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Figure 2-3. Correlation between CD25hi CD127lo CD4 T cell proportion and immune 
activation level, as indicated by CD38+HLA-DR+ CD8 T cell percentage. 
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Figure 2-4. Diminished proportions of HLA-G+ CD4 T cells in progressive HIV-1 
infection. Representative flow cytometry dot plots reflect the proportion of HLA-G+ CD4 
T cells in indicated study subjects. FMO, Fluorescence minus one. 
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Figure 2-5. Diminished proportions of HLA-G+ CD4 T cells in progressive HIV-1 
infection. Box and Whisker plots summarize the frequencies and absolute counts of 
HLA-G+ CD4 T cells in indicated study cohorts. *:p<0.05; **: p<0.01; ***: p<0.001. 
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compared to HIV-1 negative persons; this reduction was again most  pronounced in 
persons with untreated progressive disease (Figure 2-6, 2-7). We further stratified 
controllers by elite controllers (VL<50 copies/ml) and viremic controllers (50 
copies/ml <VL< 2,000 copies/ml), and compared their HLA-G+ Treg frequencies. In 
both CD4 and CD8 compartments, we observed a trend towards higher HLA-G+ 
Treg proportions in elite controllers than viremic controllers (p=0.17 for CD4 and 
p=0.0636 for CD8, figure 2-8). Notably, the relative and absolute numbers of HLA-
G expressing CD4 and CD8 T cells were positively correlated with CD4 T cell 
counts (Figure 2-9), a classic prognostic marker. Viral load in chronic progressors, 
however, does not correlate with HLA-G-expressing T cell proportions (Figure 2-10).  
Interestingly, there was an inverse relationship between the frequency of 
HLA-G expressing T cells and corresponding levels of T cell immune activation, as 
determined by surface expression of HLA-DR and CD38 (Figure 2-11). Immune 
activation level is now widely recognized as a reliable prognostic marker of HIV-1 
infection. Numerous groups have observed a strong correlation between immune 
activation level and HIV-1 disease progression, and indicated that the abnormal high 
immune activation was largely responsible for the loss of CD4 T cells (12-19). These 
correlations, therefore, strongly suggest an overall beneficial role of HLA-G-
expressing Treg in HIV-1 infection. 
Taken together, these data indicate a selective numerical decrease of HLA-
G expressing T cells in chronic progressive HIV-1 infection, and suggest that a 
reduction of HLA-G positive Tregs may contribute to higher levels of immune 
activation during progressive HIV-1 infection.  
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Figure 2-6. Diminished proportions of HLA-G+ CD8 T cells in progressive HIV-1 
infection. Representative flow cytometry dot plots reflect the proportion of HLA-G+ CD8 
T cells in indicated study subjects. FMO, Fluorescence minus one. 
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Figure 2-7. Diminished proportions of HLA-G+ CD8 T cells in progressive HIV-1 
infection. Box and Whisker plots summarize the frequencies and absolute counts of 
HLA-G+ CD8 T cells in indicated study cohorts. *:p<0.05; **: p<0.01; ***: p<0.001. 
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Figure 2-8. Proportions of HLA-G-expressing CD4 or CD8 T cells in elite controller 
(n=10) and in viremic controller (n=7). 
 
 
65 
 
 
Figure 2-9. Correlations between HLA-G+ T cell proportions and total CD4 T cell counts 
in controllers (n=23), progressors (n=27) and HIV seronegative individuals (n=15).  
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Figure 2-10. Correlations between HLA-G+ T cell proportions and plasma viral load in 
progressors (n=27).  
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Figure 2-11. Correlations between HLA-G+ T cell proportions and T cell immune 
activation. Immune activation level was determined by surface expression of CD38 and 
HLA-DR in controllers (n=19), progressors (n=20), and HIV seronegative individuals 
(n=15). 
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Depletion of peripheral HLA-G-expressing Treg cells is not likely due to tissue 
redistribution 
Since HLA-G+ Treg cells express multiple tissue homing factors (20), a redistribution 
of these cells to lymphoid tissues may be responsible for the apparent reduction of 
HLA-G-expressing Treg cells in the peripheral blood during progressive HIV-1 
infection. To investigate this, we analyzed the proportion of HLA-G+ T cells in lymph 
node and peripheral blood samples collected from patients treated with antiretroviral 
therapy (HIV-1 viral load<75 copies/ml, median CD4 count: 762/µl [IQR 528-1,152]) 
or with untreated progressive HIV-1 infection (median HIV-1 viral load: 62,750 
copies/ml [IQR 1,300-252,000], median CD4 count: 363/µl [IQR 254-610]). Among 
these patients, proportions of HLA-G+ CD4 and CD8 Treg cells in lymph nodes and 
peripheral blood were not significantly different, suggesting that 
compartmentalization of HLA-G+ Treg cells to lymph nodes does not represent the 
major reason explaining the decreased number of circulating HLA-G Treg cells in 
progressive HIV-1 infection (Figure 2-12). In contrast, classical CD25hiCD127lo Treg 
cells were significantly enriched in lymph nodes compared to peripheral blood in 
patients on and off HAART, consistent with previous results (Figure 2-13) (21). 
 
Differentiation and maturation status of HLA-G+ Treg cells 
We next investigated whether the different frequencies of HLA-G+ CD4 and 
CD8 T cells during HIV-1 infection are associated with an altered phenotypic 
differentiation or maturation status of HLA-G+ Treg cells. We found that in all study 
cohorts, the T cell subset distribution of HLA-G+ CD4 T cells into naïve, central-
memory, effector-memory and terminally-differentiated CD4 T cells was not 
complication 
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Figure 2-12. Proportion of HLA-G+ CD4 and HLA-G+ CD8 Treg cells in lymph node and 
peripheral blood. HAART: chronically-infected patients successfully treated with highly 
active antiretroviral therapy; Viremic: chronically-infected untreated patients. N=5 for 
PBMC samples from HAART-treated or progressors; n=12 for LNMC samples from 
HAART treated patients, and n=9 for LNMC samples from progressors. 
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Figure 2-13. CD25hiCD127lo CD4 Treg cells are enriched in lymph node compared to 
that in peripheral blood. HAART: chronically-infected patients successfully treated with 
highly active antiretroviral therapy; Viremic: chronically-infected untreated patients. N=5 
for PBMC samples from HAART-treated or progressors; n=12 for LNMC samples from 
HAART treated patients, and n=9 for LNMC samples from progressors. *:p<0.05; **: 
p<0.01. 
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substantially different from corresponding bulk CD4 T cells, except a subtle skew of 
terminal differentiated subset to central memory population (Figure 2-14). Moreover, 
the expression of CD57 and PD-1, two surface markers associated with senescence 
and exhaustion of T cells, was not markedly different between HLA-G+ CD4 T cells 
and the respective bulk CD4 T cells (Figure 2-15).  
In contrast, we noted that in all study cohorts, HLA-G+ CD8 T cells tended to 
have a more immature naïve or central-memory phenotype when compared to that 
of reference bulk CD8 cell populations (Figure 2-16). There was also a trend toward 
reduced surface expression of CD57 surface expression on HLA-G+ CD8 T cells in 
comparison to that on corresponding bulk CD8 T cells (Figure 2-17).  
Overall, these data indicate that during HIV-1 infection, HLA-G expressing 
CD8, but not CD4 T cells, are skewed toward a more immature differentiation status, 
but this difference is not correlated to the rates of spontaneous HIV-1 disease 
progression.  
 
HLA-G-expressing Treg cells do not inhibit functional properties of HIV-1-specific T 
cells 
A functional hallmark of classical Treg cells is their ability to inhibit antigen-
specific T cell responses (22). Prior work has shown that non-classical Treg cells 
can also inhibit proliferative properties of T cells, but their functional effects on HIV-
1-specific, or other antigen-specific T cells remain unclear (1). To investigate this, 
CFSE-labeled PBMCs from HIV-1 patients were stimulated with a pool of 
overlapping HIV-1 Gag peptides, CMV pp65 peptide pool, or PHA. The stimulated 
cells were then individually mixed with sorted autologous HLA-G+ CD4 T cells, HLA-
G+ CD8 T cells, or HLA-G- CD25+ CD4 T cells; HLA-G- CD25- CD4 or HLA-G- CD25-  
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Figure 2-14. T cell subset distribution of HLA-G-expressing CD4 T cells in indicated 
study populations. Data from corresponding bulk T cell populations are shown for 
reference purposes. *:p<0.05; **: p<0.01; ***: p<0.001. 
 
 
73 
  
 
 
 
Figure 2-15. Surface expression of CD57 and PD-1 in HLA-G- expressing CD4 T 
cells in indicated study cohorts. Data from corresponding bulk T cell populations are 
shown for reference purposes. *:p<0.05; **: p<0.01; ***: p<0.001. 
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Figure 2-16. T cell subset distribution of HLA-G-expressing CD8 T cells in indicated 
study populations. Data from corresponding bulk T cell populations are shown for 
reference purposes. *:p<0.05; **: p<0.01; ***: p<0.001. 
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Figure 2-17. Surface expression of CD57 and PD-1 in HLA-G- expressing CD8 T 
cells in indicated study cohorts. Data from corresponding bulk T cell populations are 
shown for reference purposes. *:p<0.05; **: p<0.01; ***: p<0.001. 
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CD8 conventional T cells were added as a negative control. Subsequently, 
proliferation of antigen-specific CD4 and CD8 T cells was monitored after six days of 
culture.  
These experiments demonstrated relatively strong suppressive effects of 
classical CD25+CD4 Treg on the proliferative activities of HIV-1-specific cells, 
consistent with prior reports showing potent Treg-mediated inhibition of CD8 T cell 
proliferation (23). HLA-G-expressing Tregs, however, did not significantly reduce the 
proliferation of HIV-1-specific CD4 and CD8 T cells (Figure 2-18, 2-19).  
To assess whether HLA-G-expressing Tregs influence the cytokine secretion 
properties of HIV-1-specific T cells, isolated CD3 T cells from HIV-1-infected 
persons were stimulated with overlapping Gag peptides in the presence of the HLA-
G+ CD4 T cells, HLA-G- CD25+ CD4 T cells, or HLA-G- CD25- control cells; after 16 
hours of incubation, antigen-specific secretion of interferon-γ and IL-2 was 
monitored by flow cytometry. As summarized in Figure 2-20, cytokine secretion of 
HIV-1-specific CD8 T cells did not differ following co-incubation with any of the Treg 
populations or negative control cells. Taken together, these data show that HLA-G-
expressing Tregs have limited effects on the functional activities of HIV-1-specific T 
cells, at least under the tested conditions.  
 
HLA-G expressing Tregs selectively inhibit bystander activation 
To further explore the role of HLA-G-expressing Treg cells in HIV-1 disease 
pathogenesis, we focused on how they influence T cell activation. Activation of T 
lymphocytes can either occur through direct antigenic triggering of the TCR, or by 
mechanisms involving a TCR-independent mode of T cell stimulation, commonly 
referred to as “bystander activation” (24, 25). Both of these pathways seem to  
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Figure 2-18. HLA-G-expressing Treg cells do not inhibit proliferative activities of HIV-
1, CMV-, or PHA stimulated helper T cells. (A): Representative dot plots reflect 
proliferative activities of HIV-Gag, CMV-pp65, or PHA- stimulated CD4 T cells 
following incubation with indicated autologous Treg subsets or HLA-G- CD25- control 
cells (B): Cumulative data from n=3 study subjects indicate Treg mediated 
suppressive effects, if any, on CD4 T cell proliferation. *:p<0.05. 
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Figure 2-19. HLA-G-expressing Treg cells do not inhibit proliferative activities of HIV-
1, CMV-, or PHA stimulated cytotoxic T cells. (A): Representative dot plots reflect 
proliferative activities of HIV-gag, CMV-pp65, or PHA- stimulated CD8 T cells 
following incubation with indicated autologous Treg subsets or HLA-G- CD25- control 
cells. (B): Cumulative data from n=3 study subjects indicate the Treg mediated 
suppressive effects, if any, on CD8 T cell proliferation. *:p<0.05. 
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Figure 2-20. HLA-G+ Treg cells do not affect cytokine secretion properties of HIV-1- 
specific T cells. (A): Cumulative data from n=5 study subjects indicating the proportion 
of IFN+ CD4 and CD8 T cells after co-incubation with indicated Treg subsets or 
control CD4 T cells. (B): Cumulative data from n=5 study subjects indicating the 
proportion of IL-2+ CD4 and CD8 T cells after co-incubation with indicated Treg 
subsets or control CD4 T cells. 
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contribute to the pathological immune activation observed during progressive HIV-1 
infection (18, 26), and may be influenced by the HLA-G+ Treg populations described 
in this manuscript.  
As a functional assay to investigate and quantify the effects of HLA-G+ Treg 
cells on TCR-dependent and bystander immune activation, we stimulated T cells 
with staphylococcal enterotoxin B (SEB), an antigen that elicits T cell responses by 
a broad panel of different TCR clonotypes, but cannot be recognized by T cells 
using TCR Vβ13.1 (27, 28). Immune activation in Vβ13.1-expressing T cells 
following exposure to SEB can therefore only be attributed to bystander activation, 
while immune activation in Vβ13.1-negative T cells after SEB exposure mainly 
reflects classical TCR-dependent activation.  
To analyze the effects of non-classical Tregs on immune activation, SEB-
stimulated responder T cells were individually co-cultured with autologous 
populations of sorted HLA-G+ CD4 Treg and CD25+ CD4 Treg cells; HLA-G- CD25- 
CD4 were added for control purposes. Alternatively, HLA-G+ CD8 Treg, CD25+ 
CD28- CD8 Treg or HLA-G- CD25- CD8 control cells were added to autologous 
SEB-stimulated responder T cells. On day 4 of culture, immune activation was 
measured by flow cytometric analysis of CD38 and HLA-DR surface expression in 
Vβ13.1-positive and Vβ13.1-negative T cells.  
As demonstrated in Figure 2-21, we observed that classical CD25+ Treg 
cells potently suppressed CD38/HLA-DR expression in Vβ13.1-negative T cells, 
consistent with prior reports about the immunosuppressive properties these cells 
(23). In contrast, HLA-G expressing T cells led to a significantly reduced surface 
expression of HLA-DR and CD38 on Vβ13.1-expressing T cells, but had limited 
effects on immune activation of Vβ13.1-negative cells (Figure 2-22, 2-23). This  
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Figure 2-21. Representative flow cytometry dot plots reflect CD38 expression on 
Vβ13.1+ and Vβ13.1- responder T cells. Responder cells were isolated from HIV 
seronegative individuals and activated by SEB in the presence of autologous Treg or 
conventional T cells.  
 
 
82 
 
 
Figure 2-22. Cumulative data represents relative suppression of CD38 and HLA-
DR expression on Vβ13.1+ and Vβ13.1- responder T cells following exposure to 
regulatory or conventional CD4 T cells. Responder cells were isolated from HIV 
seronegative individuals and activated by SEB, in the presence of autologous CD4 
Treg or conventional, non-suppressive CD4 T cells. Data from n=8 study subjects 
are shown. *:p<0.05; **: p<0.01; ***: p<0.001. 
 
  
83 
 
 
 
Figure 2-23. Cumulative data represents relative suppression of CD38 and HLA-
DR expression on Vβ13.1+ and Vβ13.1- responder T cells following exposure to 
regulatory or conventional CD8 T cells. Responder cells were isolated from HIV 
seronegative individuals and activated by SEB, in the presence of autologous CD8 
Treg or conventional, non-suppressive CD8 T cells. Data from n=8 study subjects 
are shown. *:p<0.05; **: p<0.01. 
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selective inhibitory effect on bystander activation was seen both for HLA-G+ CD4 
and CD8 T cells and substantially exceeded regulatory effects on bystander 
activation of classical CD25+ Treg.  
To explore reasons for the differential susceptibility of Vβ13.1-positive and 
Vβ13.1-negative responder T cells to classical and non-classical Treg, we analyzed 
the dynamics of LILRB1 surface expression on responder T cell over a 4-day 
incubation period. LILRB1 can effectively inhibit functional properties of T cells (29) 
and represents one of the highest-affinity receptors for HLA-G (30), which is 
secreted by HLA-G+ Treg cells (Figure 2-24), and responsible for the 
immunomodulatory effects of these cells (1). Interestingly, we observed that 
following TCR-dependent T cell activation, LILRB1 surface expression on 
responder T cells declined, while that on bystander subsets was stable or slightly 
increased (Figure 2-25). We also measured the expression of another HLA-G 
receptor, KIR2DL4, that is primarily expressed on NK cells and certain T cell lines 
(31, 32). However we did not observe KIR2DL4 expression on primary T cells in 
our experimental system (data not shown). Overall, these data indicate that HLA-G+ 
Treg cells differ from alternative Treg populations by their ability to potently 
suppress bystander activation of T cells, and suggest that TCR-dependent and 
TCR-independent mechanisms of immune activation are associated with altered 
susceptibilities to inhibitory effects of classical and non-classical Treg cells.  
 
HLA-G-expressing CD4 T cells are more susceptible to HIV-1 infection   
Conventional CD25+CD4 Treg cells express HIV-1 co-receptors and are targets for 
HIV-1 infection (33, 34). Direct HIV-1 infection of HLA-G+ CD4 Treg cells may 
contribute to the reduction of these cells in progressive HIV-1 infection. To 
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extention 
 
 
Figure 2-24. Expression of soluble and membrane-bound HLA-G in culture. (A): 
Western blots reflect soluble HLA-G level, cell-associated HLA-G and β-actin protein 
expression in isolated HLA-G+ and HLA-G- subsets (B): Quantitative expression of 
soluble HLA-G and cell-associated protein. HLA-G+ cells were pulled down by staining 
with a primary PE antibody followed by anti-PE beads. HLA-G- cells were collected in 
the flow through. Aliquot the same number of HLA-G+ and HLA-G- cells in FACS tubes 
with R10/50 as the culture medium. Collect cells and supernatant for westernblot 
analysis on Day 4. N=4. 
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Figure 2-25. LILRB1 expression on Vβ13.1+ T cells remain stable while that on 
Vβ13.1-  T cells decreases. Representative plots (A) and statistic analysis (B) show 
the fold change of LILRB1 expression on Vβ13.1+ and Vβ13.1- T cells during 4 days in 
culture. N=7. 
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investigate this, we infected pre-activated or non-pre-activated (directly isolated ex 
vivo) CD4 T cells with X4- or R5-tropic virus, or with VSV-G pseudotyped construct 
that causes single round HIV-1 infection. After 4 days in culture, we observed that 
HLA-G+ CD4 Treg were significantly more susceptible to HIV-1 infection than 
autologous HLA-G-negative CD4 T cells; this was true both for in vitro activated 
cells, and for cells directly infected ex-vivo (Figure 2-26, 2-27). This enhanced 
susceptibility was in line with higher expression of the HIV-1 co-receptors CXCR4 
and CCR5 on HLA-G+ CD4 Treg cells, in comparison to HLA-G-negative CD4 T 
cells (Figure 2-28 and 2-29). These data suggest that reduction of circulating HLA-
G+ Treg in progressive HIV-1 infection may, at least in part, be due to their 
enhanced susceptibility to HIV-1 infection. 
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Figure 2-26. HLA-G+ Treg cells were more susceptible to VSV-G, X4 and R5 virus 
infection than the HLA-G- cells (with pre-activation). (A) Representative flow plots 
reflect the proportion of GFP-expressing HLA-G+ or HLA-G- CD4 T cells. (B) Box and 
Whisker plots summarize the proportion of GFP-positive CD4 T cells in HLA-G+ or 
HLA-G- cells. N=10. **: p<0.01; ***: p<0.001. 
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Figure 2-27. HLA-G+ Treg cells were more susceptible to VSV-G, X4 and R5 virus 
infection than the HLA-G- cells (without pre-activation). (A) Representative flow plots 
reflect the proportion of GFP-expressing HLA-G+ or HLA-G- CD4 T cells. (B) Box and 
Whisker plots summarize the proportion of GFP-positive CD4 T cells in the HLA-G+ or 
HLA-G- cells. N=9. *:p<0.05; **: p<0.01. 
 
  
90 
 
 
 
Figure 2-28. Pre-activated HLA-G+ CD4 T cells express higher level of HIV-1 co-
receptors, CXCR4 and CCR5, than that of HLA-G- cells during in vitro infection. Box 
and Whisker plots reflect mean florescence intensity of CXCR4 and CCR5 in HLA-G+ 
or HLA-G- cells. N=10. *:p<0.05; **: p<0.01. 
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Figure 2-29. Non-activated HLA-G+ CD4 T cells express higher level of HIV-1 co-
receptors, CXCR4 and CCR5, than that of HLA-G- cells during in vitro infection. Box 
and Whisker plots reflect mean florescence intensity of CXCR4 and CCR5 in HLA-G+ 
or HLA-G- cells. N=9. *:p<0.05; **: p<0.01. 
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Discussion 
Regulatory T lymphocytes can influence immune homeostasis by 
suppressing innate and adaptive effector cell activity, and in this way may 
importantly modulate immune defense mechanisms against HIV-1 (35). The 
majority of currently available data indicate that classical CD25hiCD127lo Treg cells 
are expanded during chronic progressive HIV-1 infection (36-41) and may worsen 
spontaneous HIV-1 disease progression by potently suppressing functional 
activities of HIV-1-specific T cell responses (23). Here, we demonstrate several 
numerical and functional aspects of non-classical HLA-G expressing Treg cells in 
HIV-1 infection that clearly distinguish them from these recognized characteristics 
of classical Treg subsets. We found that absolute numbers and relative proportions 
of HLA-G expressing Treg cells are diminished in progressive HIV-1 infection, that 
they are inversely correlated to phenotypic markers of immune activation, and that 
they have a functional role for inhibiting bystander immune activation, while having 
a minimal impact on proliferative activities of HIV-1-specific T cells. Overall, these 
data suggest that HLA-G expressing Treg cells have important and unique 
functions for balancing and fine-tuning anti-viral immune activity and bystander 
immune activation during HIV-1 infection.  
 
HLA-G positive Treg cells represent a relatively recently discovered group 
of suppressive T cells that can inhibit the activation and proliferation of T cells after 
TCR triggering with CD3/CD28 antibodies. But how HLA-G+ Treg cells functionally 
compare to classical Treg subsets in terms of their ability to suppress virus-specific 
T cells or TCR-independent bystander activation of lymphocytes remained unclear. 
Our data show that HLA-G+ Treg cells do not inhibit proliferation of HIV-1 and CMV-
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specific T cells, in comparison to classical Treg cells, which can suppress T cell 
proliferation by 30-40%. In contrast, we observed an augmented ability of these 
Treg cells to inhibit TCR-independent bystander activation of T cells, using an 
assay that excludes TCR cross-reactivity as a possible source of activation in 
heterologous T cells. Together, these results suggest that HLA-G+ Treg cells differ 
from alternative Treg populations by a unique profile of suppressive functions that 
may allow for reducing bystander immune activation, while simultaneously 
minimizing inhibitory effects on virus-specific T cell immune responses. These cells 
might therefore be of particular benefit during progressive HIV-1 infection.  
 
This work demonstrates that in contrast to classical Treg cells, HLA-G 
expressing Treg population progressively decline during advanced HIV-1 infection. 
This selective loss of HLA-G+ CD4 Treg cells during advanced HIV-1 infection might 
represent an important contributory factor to the immune overactivation during 
progressive HIV-1 infection. The selective depletion of HLA-G Treg cells during 
progressive HIV-1 infection may be related to their increased susceptibility to HIV-1 
infection, which is likely due to enhanced expression of the viral co-receptors CCR5 
and CXCR4 demonstrated in this study. An upregulation of these chemokine 
receptors may also lead to elevated sequestration of HLA-G+ Treg cells into 
inflamed tissues, where these cells were indeed preferentially observed in previous 
investigations (1). However, in our study, we did not find any positive evidence for a 
selective enrichment of HLA-G+ Treg cells in lymphoid tissues, neither in HAART-
treated nor in untreated HIV-1 patients. This observation in a limited number of 
patients does not exclude the possibility of tissue compartmentalization of HLA-G 
Treg cells in HIV-1 infection, and further studies are warranted to clarify 
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mechanisms responsible for the selective loss of HLA-G+ CD4 Treg subset during 
progressive HIV-1 infection. In addition, the specific reason for the loss of HLA-G+ 
CD8 Treg cells in untreated progressive HIV-1 infection remains unclear and 
warrants further investigation. 
 
Over the recent years, HIV-1 infection has increasingly been recognized as 
a chronic inflammatory condition characterized by elevated T cell immune 
activation (42). The mechanisms leading to this abnormal immune activation are 
most likely multifactorial and include direct stimulation of T cells by HIV antigens, as 
well as direct TCR-mediated activation of T cells by alternative viral and bacterial 
antigens that challenge the host during conditions of HIV-1 associated immune 
deficiency (43-50). These TCR-dependent signals lead to the activation of 
transcription factors such as NF-κB, NFAT, C-JUN and C-FOS, which in turn 
results in phenotypic changes and effector functions, such as proliferation, 
cytotoxicity, cytokine production, and apoptosis (Figure 2-30).  
Alternatively, T cells can be activated by bystander activation, defined as 
“the activation of a T cell to produce phenotypic or functional changes through a 
mechanism independent of specific TCR stimulation” (26). It is often triggered by 
other cell-surface molecule (such as CD2) ligation or certain cytokines. The most 
well known bystander-related cytokines include IL-2, IL7, IL-12, IL15, IL-18 and 
IFN-α/β (24, 51-53) (Figure 30). These cytokines, produced by antigen-presenting 
cells, T cells, or stromal cells, induce activation and proliferation signals in the 
target cells through less well-characterized pathways. 
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Figure 2-30. Mechanisms for direct (a) and bystander (b) T-cell activation. Source: 
Bangs SC, et al: Bystander T cell activation – implications for HIV infection and 
other diseases. Trends Immunol (2006). 
 
Although TCR-independent bystander immune activation does not seem to 
play a significant role under physiologic conditions, increasing data suggest that 
bystander activation represents a major driving factor for pathological immune 
activation during progressive HIV-1 infection. For instance, bystander-activation-
related cytokines, interferon-α/β, IL-2 and IL-15, are all increased in HIV-1 infection 
and represent independent and accurate predictors of disease progression (54). 
Moreover, the majority of activated T cells in HIV-1 infected patients typically do not 
exhibit phenotypic markers of recent TCR stimulation (55), suggesting that their 
activation occurred by TCR-independent processes. In addition, activation of T cells 
specific for Influenza virus has been documented during HIV-1 infection in the 
absence of serological evidence of Influenza co-infection, or detectable TCR cross-
reactivity between HIV-1 and Influenza antigens (48).   
Interestingly, our data suggest that T cells activated by bystander 
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mechanisms have a higher susceptibility to inhibitory effects of HLA-G+ Treg, likely 
because they do not downregulate the HLA-G receptor LILRB1 in a similar way as 
T cells activated by TCR triggering. The exact reason why CD25hi Treg cells do not 
reduce bystander activation as much as they do for the directed-stimulated 
activation is unclear. One of the mechanisms that CD25hi Treg (but not HLA-G Treg) 
uses to suppress target cells is to induce TGF-β secretion (56, 57). Interestingly, it 
was reported that TGF-β receptor expression increased upon immune activation 
(58), as a part of the negative control loop. Noticeably, the directly-stimulated T cell 
population in our experiment expressed a significantly higher level of activation 
markers than that of the bystander cells (data not shown), indicating that they might 
possess a higher expression of surface TGF-β receptor, thus were more 
susceptible to CD25hi Treg’s suppressive effect. However whether or not a 
differential expression of TGF-β receptor exists, and how much does it contribute to 
the different levels of regulation by CD25hi Treg on bystander vs. directly-stimulated 
cells warrants further investigation. Taken together, these observations indicate 
that TCR-dependent and TCR-independent mechanisms of immune activation are 
associated with altered susceptibilities to classical and non-classical Treg 
populations, and shed new light on target cell characteristics that influence 
inhibitory effects of Treg cells. By selectively inhibiting the deleterious effects of 
TCR-independent bystander activation, the HLA-G+ Treg subset may provide a 
previously unrecognized form of immune protection against HIV-1 associated 
disease manifestations.  
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Chapter 3 
 
 
 
Comprehensive characterization of LAP-
expressing regulatory T cells  
in HIV-1 infection 
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Introduction 
One member of the emerging non-classical regulatory T cell populations is 
characterized by surface expression of latency-associated peptide (LAP) (1). LAP is 
the amino-terminal domain of TGF-β1 precursor. After being cleaved from the 
precursor, it remains non-covalently connected with TGF-β to prevent uncontrolled 
activation of the cognate TGF receptors (2, 3). 
 
Figure 3-1. LAP covalently binds to latent form of TGF-β. Source: Annes, J et al, 
Making sense of latent TGFbeta activation. J Cell Sci, 2003   
 
Unlike HLA-G-expressing Treg cells, which display minimal expression of CD25, 
LAP was first found on a subset of classical CD25hi CD4Treg cells. This LAP+ Treg 
subset expressed elevated levels of CTLA4, TGF-β and TGF-β receptor, and appeared 
to be more suppressive than their LAP-negative CD25hi counter partners (4). Later it 
was found that LAP itself was sufficient to define a novel CD4 Treg population; these 
LAP+ CD4 T cells lacked FoxP3 expression but were able to inhibit proliferative 
activities of T lymphocytes in vitro and in vivo (1). In addition, LAP+ Treg cells were 
different from the classical Treg populations in the surface expression level of TGF-
bRII and CD69, as well as cytokine secretion profile upon activation (1). The numeric 
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distribution and functional role of LAP+ CD4 Treg cells during HIV-1 infection is not 
known.     
In the present study, we systematically analyzed the expression and function of 
LAP-expressing Treg cells in patients with different stages of HIV-1 infection. Our 
results indicated a reduction of LAP+ CD4 Treg cell numbers, but not proportions, in 
individuals with progressive HIV-1 disease. Moreover, similar to classical 
CD25hiCD127loCD4 Treg cells, LAP+ CD4 Treg subset was able to suppress HIV-1-
specific proliferation and TCR-driven immune activation, but not TCR-independent 
bystander activation. 
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Materials and Methods 
Study participants 
HIV-infected patients and HIV-1 seronegative control persons were recruited 
according to protocols approved by the Institutional Review Board of the 
Massachusetts General Hospital in Boston.  
We have included in the study 5 patient groups with various status of HIV 
infection: 10 patients with primary infection and seroconversion within 3 months 
prior to recruitment (acutely-infected patients), 15 treatment-naïve HIV-1 infected 
individuals with chronic progressive infection (progressors), 9 HIV-1 infected 
persons successfully treated with HAART, 17 patients with spontaneous control of 
HIV-1 replication (controllers), and 11 non-HIV-infected healthy individuals (HIV 
negative).  
Among acutely-infected patients, the viremia ranges from 36,600-982,000 
copies/µl, with a median of 152,400 copies/ml; CD4 T cell count varies from 265 to 
1047/µl with a median of 489/µl. For chronic progressors, the viral load varies from 
27,700-112,000 copies/ml, with a median of 50,600 copies/ml; CD4 T cell count 
varies from 229-652/µl, with a median of 456/µl. As for HAART-treated patients, all 
of them have viremia <50 copies/ml, and their CD4 T cell count ranges from 415-
1493/µl with a median of 803/µl. For controllers, all of them have viral load <1,000 
copies/ml, and CD4 T cell count varies from 440-1415/µl, with a median of 839/µl. 
 
Immunophenotypic analysis 
Peripheral blood mononuclear cell (PBMC) were isolated from whole blood 
using Ficoll density centrifugation. PBMC were stained with LIVE/DEAD cell viability 
dye (Invitrogen) and monoclonal antibodies directed against CD4, CD25, CD127, 
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CD45RA, CCR7 (BD Biosciences), CD57 and PD-1 (Biolegend), CD8 (Invitrogen) 
and LAP (Clone 27232, R&D systems). After incubation for 20 minutes at room 
temperature, cells were fixed with PBS containing 0.5% fetal calf serum and 1% 
formaldehyde. Cells were acquired on LSR Fortessa™ Cell Analyzer (BD 
Biosciences) using DiVA software. Data were analyzed using FlowJo software (Tree 
Star).   
 
Cell isolation and sorting 
CD4 or CD8 T cells were isolated using a negative cell purification kit 
(Stemcell), according to the manufacturer’s instructions. Cell purity was >90% in all 
cases. Subsequently, Fluorescence activated cell sorting was used to divide bulk 
CD4 T cells into four subgroups: LAP- CD25hi CD4 T cells, LAP+ CD25lo CD4 T cells, 
and LAP- CD25lo CD4 T cells. For this purpose, CD4 cells were labeled with the 
respective monoclonal antibodies and viability dye, washed, and sorted on a 
FACSAria instrument (BD Biosciences) at 70 pounds per square inch.  
 
Proliferation Assay 
PBMC from HIV-1 infected individuals were stained with 0.25 µM 
carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes) and mixed with 
sorted autologous Treg populations or control T cells without regulatory activity at 
ratios of 4:1. Afterwards, cells were stimulated with a pool of overlapping peptides 
spanning the clade B consensus sequences of HIV-1 Gag (2 µg/ml per peptide). 
After incubation for 6 days in RPMI 1640 medium supplemented with 2 mM l-
glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, 10 mM Hepes, and 10% heat-
inactivated FCS, cells were washed, stained with viability dye, CD4 and CD8 
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antibodies, fixed and acquired on a LSR Fortessa flow cytometer. Suppression of T 
cell proliferation by Tregs was calculated as: (T cell proliferation (%) in the non-Treg 
co-culture – T cell proliferation (%) in the Treg co-culture)/T cell proliferation (%) in 
the non-Treg co-culture. 
 
Intracellular Cytokine Staining 
Purified CD3 T responder cells from HIV-1 patients were stained with CFSE 
as described above and subsequently mixed with sorted autologous Treg 
populations or control CD4 T cells at a ratio of 2:1. Cells were then stimulated with a 
pool of overlapping peptides spanning HIV-1 Gag (2µg/ml per peptide) in the 
presence of antibodies directed against CD28 and CD49d (2µg/ml). Cells were 
incubated for 6h at 37°C, and brefeldin A was added at 5µg/ml after the first hour of 
incubation. Afterwards, cells were stained with viability dye and antibodies against 
CD4 and CD8, fixed and permeabilized using a commercial kit (Caltag, Burlingame, 
CA), and subjected to intracellular cytokine staining with monoclonal antibodies 
against interferon-γ (Becton Dickinson). Following final washes, cells were acquired 
on a LSR Fortessa instrument. The proportion of IFN-γ+ or IL-2+ CD4 and CD8 T 
cells was determined after gating on CD3+ CFSE+ responder T cells, using FlowJo 
software.  
 
Assessment of bystander activation 
Purified CD3+ responder T cells from healthy individuals were mixed with 
sorted autologous Tregs populations or autologous control CD4 T cells without 
regulatory activities at a ratio of 2:1. Following stimulation of cells with SEB, cells 
were incubated at 37°C for 4 days. Afterwards, cells were stained with antibodies 
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against CD4, CD8, CD38, HLA-DR and Vβ13.1 and viability dye before being 
subjected to flow cytometric acquisition on a LSR Fortessa instrument. The surface 
expression of activation markers in responder T cells was analyzed after gating on 
CD3+ events. Treg-dependent suppression of bystander activation was calculated 
as: (CD38/HLA-DR -expressing T cells (%) in the non-Treg co-culture – CD38/HLA-
DR -expressing T cells in the Treg co-culture)/CD38/HLA-DR -expressing T cells (%) 
in the non-Treg co-culture).  
 
Statistical analysis 
Data are expressed as mean and standard deviation, or as box and whisker 
plots indicating the median, the 25% and 75% percentile and the minimum and 
maximum of all data. Differences between different cohorts or different experimental 
conditions were tested for statistical significance using analysis of variance 
(ANOVA), Mann-Whitney U test, Wilcoxon signed rank test, or paired/unpaired t 
tests, as appropriate. Spearman correlation was used to assess the association 
between two variables. A p-value of 0.05 was considered significant. 
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Results and Discussion 
Decreased numbers of LAP+ CD4 T cells in HIV-1 infection  
CD4 T cells expressing LAP, a membrane-bound form of TGF-β, have 
recently been characterized as an alternative, Foxp3-negative population of 
lymphocytes with immunosuppressive properties (1). To determine whether this 
non-classical population of regulatory cells is involved in HIV-1 disease 
pathogenesis, we analyzed the frequency of LAP+ CD4 T cells in our study cohorts.  
We observed no differences in proportions of LAP-expressing CD4 T cells 
across all HIV-1 infected cohorts (Figure 3-2, 3-3). Proportions of LAP+ CD8 T cells, 
which may also have regulatory activities (1), did not differ between our study 
groups (Figure 3-4, 3-5). LAP+ T cell proportions were not significantly correlated 
with CD4 T cell count (Figure 3-6), or plasma viral load (Figure 3-7). LAP-expressing 
CD4 T cell frequencies and absolute counts were positively associated with immune 
activation level, which indicated that it might serve as an activation marker in HIV-1 
infection (Figure 3-8). 
We next examined the differentiation and maturation status of LAP+ T cells. 
We did not find a substantial difference between LAP+ T and bulk T cells in terms of 
T cell subset distribution, although LAP+ CD8 T cells appeared to be slightly 
overrepresented in central-memory cells during HIV-1 infection (Figure 3-9, 3-10). 
No differences were found between the surface expression of PD-1 and CD57 on 
LAP+ T cells and bulk T cells (Figure 3-11, 3-12).  
Taken together, these results suggested a lack of direct correlation of LAP-
expressing T cells and HIV-1 disease outcome. However it did not exclude the 
possibility that these cells could still influence specific functional aspects of the 
immune system during the infection course. 
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Figure 3-2. Representative flow plots reflect proportions of LAP+ CD4 T cells in 
indicated study populations. 
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Figure 3-3. Box and Whisker plots summarize the relative proportions and absolute 
counts of LAP+ CD4 T cells in indicated study populations. **: p<0.01. 
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Figure 3-4. Representative flow plots reflect proportions of LAP+ CD8 T cells in 
indicated study populations. 
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Figure 3-5. Box and Whisker plots summarize the relative proportions and absolute 
counts of LAP+ CD8 T cells in indicated study populations. *:p<0.05. 
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Figure 3-6. Correlations between proportions of LAP+ T cells and CD4 T cells counts 
in controllers (n=16), progressors (n=14) and HIV- persons (n=7).  
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Figure 3-7. Correlations between proportions of LAP+ T cells and plasma viral load in 
progressors (n=14).  
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Figure 3-8. Correlations between proportions of LAP+ T cells and T cell immune 
activation level, determined by surface expression of CD38 and HLA-DR in controllers 
(n=13), progressors (n=7), and HIV- persons(n=6).  
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Figure 3-9. T cell subset distribution of LAP-expressing CD4 T cells in indicated study 
populations. Data from corresponding bulk T cell populations are also shown for 
reference purposes. *:p<0.05; **:p<0.01; ***:p<0.001. 
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Figure 3-10. T cell subsets distribution of LAP-expressing CD8 T cells in indicated 
study populations. Data from corresponding bulk T cell populations are also shown for 
reference purposes. *:p<0.05; **:p<0.01; ***:p<0.001. 
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Figure 3-11. Surface expression of CD57 and PD-1 in LAP- expressing CD4 T cells in 
indicated study cohorts. Data from corresponding bulk T cell populations are also 
shown for reference purposes. *:p<0.05; **:p<0.01; ***:p<0.001. 
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Figure 3-12. Surface expression of CD57 and PD-1 in LAP- expressing CD8 T cells in 
indicated study cohorts. Data from corresponding bulk T cell populations are also 
shown for reference purposes. *:p<0.05; **:p<0.01; ***:p<0.001. 
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LAP-expressing Treg weakly inhibit functional properties of HIV-1-specific CD8 T 
cells 
It has been shown that LAP-expressing CD4 T cells suppress poly-clonal T 
cell proliferation (1), but their functional effects on HIV-1-specific T cells remain 
unclear. To investigate this, CFSE-labeled PBMCs from HIV-1 patients were 
stimulated with a pool of overlapping HIV-1 gag peptides. The stimulated cells were 
then individually mixed with sorted autologous LAP+ CD25- CD4 T cells, LAP- CD25+ 
CD4 T cells, or a control population of LAP- CD25- CD4 conversional T cells. 
Subsequently, proliferation of HIV-specific CD8 T cells was monitored after six days 
of culture.  
The results confirmed the strong suppressive effects of classical CD25+ Treg 
cells on the proliferative activities of HIV-1-specific cells (Figure 3-13) (5). 
Interestingly, LAP-expressing Treg subset also seemed to be able to reduce the 
proliferation of HIV-1-specific CD8 T cells, although this effect was attenuated as 
compared to that of CD25hiCD4 Treg cells (Figure 3-13).  
To assess whether LAP+ CD4 T cells influence the cytokine secretion 
properties of HIV-1-specific T cells, isolated CD3 T cells from HIV-1-infected 
persons were stimulated with overlapping gag peptides in the presence of the LAP+ 
CD25- CD4 T cells, LAP- CD25+ CD4 T cells, or LAP- CD25- control cells; after 16 
hours of incubation, HIV-specific secretion of interferon-γ and IL-2 was monitored by 
flow cytometry. As summarized in Figure 3-14, cytokine secretion of HIV-1-specific 
CD8 T cells did not differ following co-incubation with any of the Treg populations or 
negative control cells.  
Taken together, these data show that LAP-expressing Tregs have limited 
effects on the functional activities of HIV-1-specific CD8 T cells.  
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Figure 3-13. LAP-expressing Treg cells weakly inhibit proliferative activities of HIV-1 
stimulated cytotoxic T cells. (A): Representative dot plots reflect proliferative activities 
of HIV-1 CD8 T cells following incubation with indicated autologous Treg subsets or 
LAP- CD25- control cells. (B): Cumulative data from n=8 study subjects indicate Treg 
mediated suppression of CD8 T cell proliferating. *:p<0.05; ***:p<0.001. 
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Figure 3-14. LAP-expressing Treg cells do not affect cytokine secretion properties 
of HIV-1- specific T cells. (A): Cumulative data from n=5 study subjects indicate the 
proportion of IFN+ CD4 and CD8 T cells after co-incubation with indicated Treg 
subsets or control CD4 T cells. (B): Cumulative data from n=5 study subjects 
indicating the proportion of IL-2+ CD4 and CD8 T cells after co-incubation with 
indicated Treg subsets or control CD4 T cells. 
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LAP expressing Treg cells do not inhibit bystander activation 
To further explore the role of LAP-expressing Treg cells in HIV-1 disease  
pathogenesis, we focused on how they influence T cell activation. We employed a 
similar experimental system as in the HLA-G study: we stimulated responder T cells 
with SEB, and co-cultured them with autologous populations of sorted LAP+ CD25- 
CD4 Treg cells, LAP- CD25+ CD4 Treg cells, or a control LAP- CD25- CD4 
population. On day 4 of culture, measured surface expression of CD38 and HLA-DR 
on Vβ13.1+ and Vβ13.1- T cells.  
Interestingly, we did not observe the same effect as we did with HLA-G-
expressing Treg cells. Rather, LAP-expressing CD4 cells acted more like CD25hi 
classical Treg cells in that they selectively suppressed the TCR-dependent 
activation of the Vβ13.1- population, though to a lesser extent than classical Treg 
subset (Figure 3-15, 3-16).  
Overall these data suggested that LAP-expressing CD4 Treg cells have 
limited functions for regulating HIV-1 disease progression. These cells did not affect 
HIV-1-specific cytokine secretion or bystander activation, while moderately suppress 
HIV-1 specific CD8 T cell proliferation. These functional data are in line with these 
cells’ weak correlation to HIV-1 disease outcome. 
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Figure 3-15. Representative flow cytometry dot plots reflect CD38 expression on 
Vβ13.1+ and Vβ13.1- responder T cells. Responder cells were isolated from HIV 
seronegative individuals and activated by SEB, in the presence of autologous CD4 
Treg or conventional CD4 T cells.  
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Figure 3-16. Cumulative data represent relative suppression of CD38 and HLA-DR on 
Vβ13.1+ and Vβ13.1- responder T cells following exposure to SEB and co-incubation 
with CD4 Treg cell populations or control T cells. Data from n=8 study subjects are 
shown. *:p<0.05; **:p<0.01. 
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Chapter 4 
 
 
 
 
 
Conclusions 
130 
Studying the role of regulatory T cells during HIV-1 infection may be of critical 
importance, given the demonstrated association of immune activation with HIV disease 
progression, and that these cells may have a critical influence on immune defense and 
immune activation in HIV-1 patients. On the one hand, one could hypothesize that Treg 
cells could suppress host immune responses elicited against the virus, therefore 
accelerating disease progression; on the other hand, Treg cells may lead to a better 
disease outcome by actively inhibiting over-activation of the immune system, which 
may cause more damage to the organisms than the infection itself. Classical Treg cells 
appear to be expanded during chronic HIV-1 infection, and contribute to acceleration of 
HIV-1 infection by inhibiting HIV-1-specific CTL responses (1-6).  
This thesis aims to determine the overall role of non-classical (Foxp3 negative), 
HLA-G-expressing (Chapter 2) and LAP-expressing (Chapter 3) Treg cells in HIV-1 
infection. To this end, we compared the relative proportions and absolute numbers of 
HLA-G- and LAP-expressing Treg cells across patients with different disease stages. 
We also correlated the frequencies of these Treg cells with prognostic markers, such 
as CD4 T cell counts and immune activation levels. Our results suggest a reduction in 
both of the frequency and number of HLA-G+ Treg cells in progressive HIV-1 disease 
courses, which is strongly correlated with low CD4 T cell counts and high levels of 
immune activation. In contrast, no apparent correlation was found between frequencies 
of LAP+ Treg cells and HIV-1 disease outcomes. Either way, these associations clearly 
distinguish both non-classical Treg populations from the classical Treg cells.  
Furthermore, our functional studies indicate that HLA-G+ Treg cells specifically 
inhibit TCR-independent bystander activation, while having minimal impact on TCR-
driven T cell activation. Because bystander activation is prominent in chronic HIV-1 
infection and can directly lead to cell injury and cell death (7-9), the ability to inhibit 
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such processes could have a significant contribution to HIV-1 disease control. More 
importantly, this suppression of bystander activation is not achieved at the cost of 
inhibiting HIV-1-specific immune responses. In fact, HLA-G+ Treg cells exhibit a 
minimal effect, if any, on HIV-1-specific helper T cell and cytotoxic T cell response 
compared to CD25hi Treg cells’. This distinctive ability to fine-tune anti-viral immunity 
may explain the strong positive association between the frequencies of HLA-G-
expressing cells and preservation of sufficient CD4 T cell counts in untreated HIV-1 
patients. 
We have shown that HLA-G-expressing Treg cells are able to suppress 
bystander immune activation of conventional T cells. Moreover, this suppression is 
associated with the persistent expression of LILRB1 (HLA-G’s receptor) on these 
bystander cells. In the mean time, TCR-dependent T cell activation leads to LILRB1 
downregulation, and makes cells resistant to immunomodulatory effects of HLA-G+ 
Treg cells. Further studies involving siRNA knock-down or protein blocking of LILRB1 
could confirm its role for mediating suppressive effects of HLA-G Treg cells. In addition, 
it may be useful to explore downstream pathways that are involved in modulating cells 
activated by TCR-independent, “bystander” mechanisms.  
Interestingly, we have shown that similar to conventional CD25hi T cells (10, 11), 
HLA-G-expressing CD4 Treg cells express high levels of the HIV-1 co-receptors 
CXCR4 and CCR5, and are highly susceptible to HIV-1 infection. This susceptibility 
may explain the reduction of HLA-G+ CD4 Treg cells seen in chronic progressors, 
whose viral loads are significantly higher and more pcersistent than those of controllers. 
In addition, the specific reason for the loss of HLA-G+ CD8 Treg cells in untreated 
progressive HIV-1 infection remains unclear and warrants further investigation.  
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Our investigations focused mostly on the functional quantitative changes of 
HLA-G-expressing Treg cells. It is possible that the quality of these cells also change 
during the course of HIV infection. For example, it was shown that in HIV-infected 
patients, whose Treg cell number was reduced, CD4 effector T cells became more 
sensitive to CD25hi CD4 Treg cells’ immunoregulation (12). We could analyze if HLA-G 
Treg cells also have this “compensating” mechanisms, by isolating HLA-G Treg cells 
from HIV-1 infected patients and from healthy individuals, and comparing their 
suppressive efficiency.  
 
The work presented in this thesis opens new questions that warrant future 
investigations. An important next step would be to see how these non-classical Treg 
cells behave in vivo in animal models of HIV-1 infection. Using this approach, one 
could address the following questions: Is depletion of HLA-G+ Treg cells accelerating 
disease progression? Do their proportion/number correlate with disease outcome? 
Could they still suppress bystander activation while maintain a minimum impact on 
HIV-1-specific responses? As HIV-1 is a primate lentivirus that does not infect small 
laboratory animals like mice, most of the current knowledge about AIDS has come from 
studies of nonhuman primates, which support replication of SIV, the origin and a close 
relative of HIV-1 (13). Although the SIV/primate models are invaluable for studying the 
disease pathogenesis (14), the divergence between SIV and HIV-1, as well as the 
differences in the MHC class I alleles and TCR repertoire should nevertheless be noted. 
Because of these differences, the epitope-specific CTL responses directed against SIV 
in macaques may not be comparable to the CTL responses induced against human 
HIV-1. The recent generation of the humanized BLT (bone marrow, liver, thymus) 
mouse model may be useful for these investigations. The BLT model utilizes the 
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engraftment of human fetal thymic and liver tissues along with human fetal liver–
derived CD34+ hematopoietic stem cells (HSCs), which support the development of a 
relatively complete human immune system in a mouse. This system was shown to be 
capable of inducing very comparable HIV-1-specific T cell responses upon viral 
infection in humans (15). The result of this study may shed light on a previously 
unrecognized form of immune protection against HIV-1 associated disease 
manifestations in vivo.  
 
Further, we have analyzed the regulatory properties of two non-classical Treg 
populations, HLA-G- and LAP- expressing Treg subsets, in HIV-1 disease progression. 
However, the role of other non-classical Treg cells, including but not limited to 
CD25+CD28- CD8+T cells (16), ϒσ-TCT+ T cells (17), Tr1/Th3 T cells (18, 19), NKT 
cells (20), CD8+ veto cells (21), and αβ-TCR+CD4-CD8- T cells (22), remains to be 
determined. In addition, the roles of regulatory macrophages (23, 24) and tolerogenic 
dendritic cells (25, 26) in HIV-1 infection were not known. Investigations on these 
regulatory subsets may be helpful for understanding the complex immunoregulatory 
mechanisms associated with HIV-1 infection in humans.  
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